b'<?xml version="1.0" encoding="utf-8"?>\n<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">\n<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">\n    \n    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />\n        <!-- AppResources meta begin -->\n        <script type="text/javascript">var ncbi_startTime = new Date();</script>\n        <!-- AppResources meta end -->\n        \n        <!-- TemplateResources meta begin -->\n        <meta name="paf_template" content="" />\n\n        <!-- TemplateResources meta end -->\n        \n        <!-- Logger begin -->\n        <meta name="ncbi_db" content="pmc" /><meta name="ncbi_pdid" content="article" /><meta name="ncbi_acc" content="" /><meta name="ncbi_domain" content="phenaturepg" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/articles/PMC2898770/" /><meta name="ncbi_app" content="pmc" />\n        <!-- Logger end -->\n        \n        <title>Co-lethality studied as an asset against viral drug escape: the HIV protease case</title>\n        \n        <!-- AppResources external_resources begin -->\n        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>\n\n        <!-- AppResources external_resources end -->\n        \n        <!-- Page meta begin -->\n        <meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898770/" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="citation_journal_title" content="Biology Direct" /><meta name="citation_title" content="Co-lethality studied as an asset against viral drug escape: the HIV protease case" /><meta name="citation_authors" content="Sophie Brouillet, Thomas Valere, Emmanuelle Ollivier, Laurent Marsan, Anne Vanet" /><meta name="citation_date" content="2010" /><meta name="citation_volume" content="5" /><meta name="citation_doi" content="10.1186/1745-6150-5-40" /><meta name="citation_abstract_html_url" content="/pmc/articles/PMC2898770/?report=abstract" /><meta name="citation_pmid" content="20565756" /><meta name="DC.Title" content="Co-lethality studied as an asset against viral drug escape: the HIV protease case" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="Nature Publishing Group" /><meta name="DC.Contributor" content="Sophie Brouillet" /><meta name="DC.Contributor" content="Thomas Valere" /><meta name="DC.Contributor" content="Emmanuelle Ollivier" /><meta name="DC.Contributor" content="Laurent Marsan" /><meta name="DC.Contributor" content="Anne Vanet" /><meta name="DC.Date" content="2010" /><meta name="DC.Identifier" content="10.1186/1745-6150-5-40" /><meta name="DC.Language" content="en" /><meta property="og:title" content="Co-lethality studied as an asset against viral drug escape: the HIV protease case" /><meta property="og:type" content="article" /><meta property="og:description" content="Co-lethality, or synthetic lethality is the documented genetic situation where two, separately non-lethal mutations, become lethal when combined in one genome. Each mutation is called a &quot;synthetic lethal&quot; (SL) or a co-lethal. Like invariant positions, ..." /><meta property="og:url" content="https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2898770/" /><meta property="og:site_name" content="PubMed Central (PMC)" /><meta property="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/pmc-logo-share.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbi" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/3.14.1/pmc_extras_prnt.min.css" type="text/css" media="print" /><script type="text/javascript" src="/corehtml/pmc/js/common.min.js">//</script><script type="text/javascript" src="/corehtml/pmc/js/NcbiTagServer.min.js">//</script><meta name="citationexporter" content="backend:\'https://api.ncbi.nlm.nih.gov/lit/ctxp/v1/pmc/\'" /><script type="text/javascript" src="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/jquery.citationexporter.min.js">//</script><link rel="stylesheet" href="https://www.ncbi.nlm.nih.gov/corehtml/pmc/ctxp/citationexporter.css" type="text/css" /><script type="text/javascript">window.name="mainwindow";</script><style type="text/css">.pmc-wm {background:transparent repeat-y top left;background-image:url(/corehtml/pmc/pmcgifs/wm-phenaturepg.gif);background-size: auto, contain}</style><style type="text/css">.print-view{display:block}</style><style type="text/css">\n        div.pmc_para_cit li.highlight,\n        div.pmc_para_cit li.highlight .one_line_source\n        { background: #E0E0E0; }\n        a.bibr.highlight { background: #E0E0E0; } \n      </style><meta name="cited_in_systematic_reviews" content="" /><link rel="alternate" type="application/epub+zip" href="/pmc/articles/PMC2898770/epub/" /><link rel="alternate" type="application/pdf" href="/pmc/articles/PMC2898770/pdf/13062_2010_Article_223.pdf" />\n\n        <!-- Page meta end -->\n    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="8A1B093EE9A3EA01000000000661065E.m_8" />\n<meta name=\'referrer\' content=\'origin-when-cross-origin\'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4048120/3846471/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/3881636/3579733/4062871/12930/3964959/3855473/4047625/3854974/3854955/4076335/4128070/9685/3549676/3609192/3609193/3609213/3395586/4143404.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/css/3411343/3882866/4157116.css" media="print" /></head>\n    <body class="article">\n        <div class="grid">\n            <div class="col twelve_col nomargin shadow">\n                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->\n                <div class="sysmessages">\n                    <noscript>\n\t<p class="nojs">\n\t<strong>Warning:</strong>\n\tThe NCBI web site requires JavaScript to function. \n\t<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>\n\t</p>\n\t</noscript>\n                </div>\n                <!--/.sysmessage-->\n                <div class="wrap">\n                    <div class="page">\n                        <div class="top">\n                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main\n                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to\n                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>\n                            <div class="header">\n    <div class="res_logo">\n  <h1 class="img_logo"><a href="/pmc/" class="pmc_logo offscreen">PMC</a></h1>\n  <div class="NLMLogo">\n    <a href="https://www.nlm.nih.gov/" title="US National Library of Medicine">US National Library of Medicine</a>\n    <br />\n    <a href="https://www.nih.gov/" title="National Institutes of Health">National Institutes of Health</a>\n  </div>\n</div>\n    <div class="search"><form method="get" action="/pmc/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="pmc" selected="selected" class="last" data-ac_dict="pmc-search-autocomplete">PMC</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc" data-ac_dict="pmc-search-autocomplete">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search PMC. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:\'pmc-search-autocomplete\',disableUrl:\'NcbiSearchBarAutoComplCtrl\'" autocomplete="off" data-sbconfig="ds:\'no\',pjs:\'no\',afs:\'yes\'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>\n                        <a href="/pmc/advanced/">Advanced</a>\n                    </li><li>\n                        <a href="/pmc/journals/">Journal list</a>\n                    </li><li class="help">\n                        <a target="_blank" href="/books/NBK3825/">Help</a>\n                    </li></ul></div>\n</div>\n\n                            \n                            \n                        <!--<component id="Page" label="headcontent"/>-->\n                            \n                        </div>\n                        <div class="content">\n                            <!-- site messages -->\n                            <div class="container">\n    <div id="maincontent" class="content eight_col col">\n        <div class="navlink-box">\n            <ul class="page-breadcrumbs inline_list small"><li class="journal-list"><a href="/pmc/journals/" class="navlink">Journal List</a></li><li class="article-entrez-filter"><a href="/pmc/?term=Nature%20Public%20Health%20Emergency%20Collection[filter]" class="navlink">Nature Public Health Emergency Collection</a></li><li class="accid">PMC2898770</li></ul>\n        </div>\n\n        <!-- Journal banner -->\n        <div class="pmc-page-banner whole_rhythm"><div class="banner-generic-logo-background inline_block"><div class="banner-journal-publisher-over-image"><div class="banner-journal-name bl-jtitle-phenaturepg">Biology Direct</div><div class="banner-publisher-name">Nature Publishing Group</div></div></div></div>\n        \n        <!--component id=\'MainPortlet\' label=\'search-reference\'/-->\n        \n        <!-- Book content -->\n        <div class="">\n            \n        \n            \n            <div class="hide-overflow article lit-style content pmc-wm slang-all page-box"><!--main-content--><div class="jig-ncbiinpagenav" data-jigconfig="smoothScroll: false, allHeadingLevels: [\'h2\'], headingExclude: \':hidden\'"><div class="fm-sec half_rhythm no_top_margin"><div class="fm-citation half_rhythm no_top_margin clearfix"><div class="inline_block eight_col va_top"><div><div><span class="cit"><span id="pmcmata">Biol Direct</span>. 2010; 5: 40. </span></div><div><span class="fm-vol-iss-date">Published online 2010 Jun 17. </span>  <span class="doi">doi:\xc2\xa0<a href="//dx.doi.org/10.1186%2F1745-6150-5-40" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CFront%20Matter&amp;TO=Content%20Provider%7CCrosslink%7CDOI">10.1186/1745-6150-5-40</a></span></div></div></div><div class="inline_block four_col va_top show-overflow align_right"><div class="fm-citation-ids"><div class="fm-citation-pmcid"><span class="fm-citation-ids-label">PMCID: </span><span>PMC2898770</span></div><div class="fm-citation-pmid">PMID: <a href="/pubmed/20565756">20565756</a></div></div></div></div><h1 class="content-title">Co-lethality studied as an asset against viral drug escape: the HIV protease case</h1><div class="half_rhythm"><div class="contrib-group fm-author"><a href="/pubmed/?term=Brouillet%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20565756" class="affpopup" co-rid="_co_idm139967178428224" co-class="co-affbox">Sophie Brouillet</a>,<sup>1,</sup><sup>3</sup> <a href="/pubmed/?term=Valere%20T%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20565756" class="affpopup" co-rid="_co_idm139967224797552" co-class="co-affbox">Thomas Valere</a>,<sup>1</sup> <a href="/pubmed/?term=Ollivier%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20565756" class="affpopup" co-rid="_co_idm139967170312112" co-class="co-affbox">Emmanuelle Ollivier</a>,<sup>1,</sup><sup>3</sup> <a href="/pubmed/?term=Marsan%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20565756" class="affpopup" co-rid="_co_idm139967173863040" co-class="co-affbox">Laurent Marsan</a>,<sup>4</sup> and  <a href="/pubmed/?term=Vanet%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20565756" class="affpopup" co-rid="_co_idm139967174175440" co-class="co-affbox">Anne Vanet</a><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup><sup>1,</sup><sup>2,</sup><sup>5</sup></div><div style="display:none" class="contrib-group aff-tip"><div id="_co_idm139967178428224"><h3 class="no_margin">Sophie Brouillet</h3><p><sup>1</sup>Atelier de Bio Informatique, F-75005 Paris, France </p><p><sup>3</sup>Universit&#x000e9; Pierre et Marie Curie, UMR 7138, Paris 6, F-75005 Paris, France </p><div>Find articles by <a href="/pubmed/?term=Brouillet%20S%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20565756">Sophie Brouillet</a></div></div><div id="_co_idm139967224797552"><h3 class="no_margin">Thomas Valere</h3><p><sup>1</sup>Atelier de Bio Informatique, F-75005 Paris, France </p><div>Find articles by <a href="/pubmed/?term=Valere%20T%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20565756">Thomas Valere</a></div></div><div id="_co_idm139967170312112"><h3 class="no_margin">Emmanuelle Ollivier</h3><p><sup>1</sup>Atelier de Bio Informatique, F-75005 Paris, France </p><p><sup>3</sup>Universit&#x000e9; Pierre et Marie Curie, UMR 7138, Paris 6, F-75005 Paris, France </p><div>Find articles by <a href="/pubmed/?term=Ollivier%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20565756">Emmanuelle Ollivier</a></div></div><div id="_co_idm139967173863040"><h3 class="no_margin">Laurent Marsan</h3><p><sup>4</sup>Universit&#x000e9; de Versailles Saint Quentin, UMR 8144, &#x000c9;quipe AOC, Laboratoire PRiSM, F-78035 Versailles, France </p><div>Find articles by <a href="/pubmed/?term=Marsan%20L%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20565756">Laurent Marsan</a></div></div><div id="_co_idm139967174175440"><h3 class="no_margin">Anne Vanet</h3><p><sup>1</sup>Atelier de Bio Informatique, F-75005 Paris, France </p><p><sup>2</sup>Universit&#x000e9; Paris Diderot, Paris 7, F-75013 Paris, France </p><p><sup>5</sup>INSERM, U973, F-75013 Paris, France </p><div>Find articles by <a href="/pubmed/?term=Vanet%20A%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=20565756">Anne Vanet</a></div></div></div></div><div class="fm-panel half_rhythm"><div class="togglers"><a href="#" class="pmctoggle" rid="idm139967162271856_ai">Author information</a> <a href="#" class="pmctoggle" rid="idm139967162271856_an">Article notes</a> <a href="#" class="pmctoggle" rid="idm139967162271856_cpl">Copyright and License information</a> <a href="/pmc/about/disclaimer/">Disclaimer</a></div><div class="fm-authors-info fm-panel hide half_rhythm" id="idm139967162271856_ai" style="display:none"><div class="fm-affl" lang="en" id="Aff1"><sup>1</sup>Atelier de Bio Informatique, F-75005 Paris, France </div><div class="fm-affl" lang="en" id="Aff2"><sup>2</sup>Universit&#x000e9; Paris Diderot, Paris 7, F-75013 Paris, France </div><div class="fm-affl" lang="en" id="Aff3"><sup>3</sup>Universit&#x000e9; Pierre et Marie Curie, UMR 7138, Paris 6, F-75005 Paris, France </div><div class="fm-affl" lang="en" id="Aff4"><sup>4</sup>Universit&#x000e9; de Versailles Saint Quentin, UMR 8144, &#x000c9;quipe AOC, Laboratoire PRiSM, F-78035 Versailles, France </div><div class="fm-affl" lang="en" id="Aff5"><sup>5</sup>INSERM, U973, F-75013 Paris, France </div><div><span class="fm-affl">Sophie Brouillet, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="rf.cmpu@telliuorb.eihpos" class="oemail">rf.cmpu@telliuorb.eihpos</a></span>.</div><div><a href="#idm139967162271856aff-info">Contributor Information</a>.</div><div><sup><img src="/corehtml/pmc/pmcgifs/corrauth.gif" alt="corresponding author" /></sup>Corresponding author.</div></div><div class="fm-article-notes fm-panel hide half_rhythm" id="idm139967162271856_an" style="display:none"><div class="fm-pubdate half_rhythm">Received 2010 Jun 6; Accepted 2010 Jun 17.</div></div><div class="permissions fm-panel half_rhythm hide" id="idm139967162271856_cpl" style="display:none"><div class="fm-copyright half_rhythm"><a href="/pmc/about/copyright/">Copyright</a> &#x000a9; Brouillet et al; licensee BioMed Central Ltd. 2010</div><div class="license half_rhythm">This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.</div></div></div><div id="pmclinksbox" class="links-box whole_rhythm"><div class="fm-panel"><div>This article has been <a href="/pmc/articles/PMC2898770/citedby/">cited by</a> other articles in PMC.</div></div></div></div><div class="sec"></div><div id="Abs1" lang="en" class="tsec sec"><h2 class="head no_bottom_margin" id="Abs1title">Abstract</h2><!--article-meta--><div><div id="__sec1" class="sec sec-first"><h3 id="__sec1title">Background</h3><p id="__p1" class="p p-first-last">Co-lethality, or synthetic lethality is the documented genetic situation where two, separately non-lethal mutations, become lethal when combined in one genome. Each mutation is called a "synthetic lethal" (SL) or a co-lethal. Like invariant positions, SL sets (SL linked couples) are choice targets for drug design against fast-escaping RNA viruses: mutational viral escape by loss of affinity to the drug may induce (synthetic) lethality.</p></div><div id="__sec2" class="sec"><h3 id="__sec2title">Results</h3><p id="__p2" class="p p-first-last">From an amino acid sequence alignment of the HIV protease, we detected the potential SL couples, potential SL sets, and invariant positions. From the 3D structure of the same protein we focused on the ones that were close to each other and accessible on the protein surface, to possibly bind putative drugs. We aligned 24,155 HIV protease amino acid sequences and identified 290 potential SL couples and 25 invariant positions. After applying the distance and accessibility filter, three candidate drug design targets of respectively 7 (under the flap), 4 (in the cantilever) and 5 (in the fulcrum) amino acid positions were found.</p></div><div id="__sec3" class="sec"><h3 id="__sec3title">Conclusions</h3><p id="__p3" class="p p-first-last">These three replication-critical targets, located outside of the active site, are key to our anti-escape strategy. Indeed, biological evidence shows that 2/3 of those target positions perform essential biological functions. Their mutational variations to escape antiviral medication could be lethal, thus limiting the apparition of drug-resistant strains.</p></div><div id="__sec4" class="sec"><h3 id="__sec4title">Reviewers</h3><p id="__p4" class="p p-first-last">This article was reviewed by Arcady Mushegian, Shamil Sunyaev and Claus Wilke.</p></div><div id="__sec5" class="sec sec-last"><h3 id="__sec5title">Electronic supplementary material</h3><p id="__p5" class="p p-first-last">The online version of this article (doi:10.1186/1745-6150-5-40) contains supplementary material, which is available to authorized users.</p></div></div><div class="sec"><strong class="kwd-title">Keywords: </strong><span class="kwd-text">Maximal Clique, Ancestral Sequence, Synthetic Lethal, Invariant Position, Viral Escape</span></div></div><div id="Sec1" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec1title">Background</h2><p id="__p6" class="p p-first">RNA viruses alone include 350 different human pathogens. Most are the agents of newly emerging diseases. Recent concerns for actual or feared pandemics (SARS, avian flu, or swine flu viruses) all raised the challenge to quickly come up with solutions. Worldwide, over 100 million influenza cases occur each year, 170 million people carry HCV, and 33 million HIV. RNA viruses generally have very high mutation rates as they use polymerases which cannot find and fix mistakes, and are therefore unable to conduct genomic repair of damaged genetic material. Under selective pressure, this error-prone replication can confer drug resistance. Since AIDS appeared, many new drugs have been created and used against RNA viruses, which in turn readily evolved drug-resistant strains, a now predictable process and an unprecedented public health issue. HIV mutant strains that escape antiviral compounds have been extensively documented [<a href="#CR1" rid="CR1" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807584">1</a>], and one of influenza\'s main treatments, tamiflu, was quickly escaped from by an influenza strain which then spread surprisingly fast across the planet [<a href="#CR2" rid="CR2" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807572">2</a>]. It now becomes clearer that future antiviral strategies should address this issue from the outset, aggressively striving to prevent viral escape. To deal with this, several directions have been explored since a decade: the structures of resistant proteins [<a href="#CR3" rid="CR3" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807597">3</a>], second generation drugs that can bind resistant proteins [<a href="#CR4" rid="CR4" class=" bibr popnode">4</a>], drug target polymorphism analysis in order to define "super drugs" [<a href="#CR5" rid="CR5" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807577">5</a>], definition of new targets, such as protein backbones [<a href="#CR6" rid="CR6" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807562">6</a>] or dimeric proteins\' monomers, in order to block them before dimerisation [<a href="#CR7" rid="CR7" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807576">7</a>]. Overall, although individual case solutions were found, no general solution has emerged yet.</p><p id="__p7">It is now documented that drug resistance is due to at least one mutated amino acid, so researchers have recommended, that invariant viral amino acids should be targeted by future new drugs [<a href="#CR8" rid="CR8" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807559">8</a>]. The rationale is that mutations in invariant positions always damage a critical biological function, resulting in non-replicative viruses. For exemple, zanamivir is a broad inhibitor of neuraminidase, an influenza glycoprotein, probably because it interacts with invariant amino acids inside the enzyme active site [<a href="#CR9" rid="CR9" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807589">9</a>]. Ceccherini <em>et al</em>. [<a href="#CR10" rid="CR10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807555">10</a>&#x02013;<a href="#CR12" rid="CR12" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807601">12</a>] identified new conserved residues for the HIV protease, reverse transcriptase and integrase, and mapped them on the 3D protein structure to help to design a new structure-based escape-resistant inhibitor.</p><p id="__p8">Unfortunately, sometimes, invariant positions are too few to constitute a proper docking site for a drug. For example, 63% of the HIV protease amino acids are variable [<a href="#CR13" rid="CR13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807573">13</a>]. In an effort to gather enough replicativity-critical amino acids for a possible docking site, we propose to also target synthetic lethals (SL, or co-lethals). Synthetic lethality is the lethality resulting when two, individually survivable, mutations, are co-present [<a href="#CR14" rid="CR14" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807591">14</a>]. Each mutation is then called a synthetic lethal. Analysis of SLs is a powerful tool to understand genetic interactions and essential metabolic pathways. Synthetic lethality has been extensively used to study gene products\' interactions in the secretion pathway in yeast [<a href="#CR15" rid="CR15" class=" bibr popnode">15</a>], in bacteria [<a href="#CR16" rid="CR16" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807592">16</a>] and even to identify anticancer agents [<a href="#CR17" rid="CR17" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807599">17</a>]. It was noticed that, in many cases, the double mutants identified had their co-lethal mutations in 2 different genes. A few yeast studies analyzed protein structure-function aspects, revealing intragenic synthetic lethals [<a href="#CR18" rid="CR18" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807587">18</a>], i.e. cases where the 2 co-lethal mutations occur in one same gene. Little SL research has been undertaken on viruses. Researchers were rather on a quest for the opposite situation, where one crippling mutation is rescued by a second, intragenic, suppressor mutation, the second restoring the function lost due to the first mutation [<a href="#CR19" rid="CR19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807558">19</a>, <a href="#CR20" rid="CR20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807593">20</a>]. They also found few, under-represented intragenic suppressors, which actually turned out to be SLs.</p><p id="__p9">In line with our patented model [<a href="#CR21" rid="CR21" class=" bibr popnode">21</a>] we chose to focus on intragenic synthetic lethals in the HIV protease. As mentioned above, the number of replicativity-critical amino acids available for drug docking should be maximized, invariant amino acids being not numerous enough, and one single SL couple being possibly too little. So we propose to add larger "SL sets" rather than one single SL couple. By "SL set", we mean a set of SL couples that are connected to each other. We choose to add also the invariant position being in the vicinity of the SL set. Indeed, a set of positions containing invariant amino acids plus an SL set may be large enough a target for putative antiviral drugs.</p><p id="__p10" class="p p-last">To test this anti-escape approach in practice, we study the HIV-1 protease from the B sub-type. This protein is a 99 amino acids homodimeric aspartic protease and its substrate-binding pocket includes the D25-T26-G27 catalytic triad and flap regions, which presumably open and close to allow entry and binding of substrates or inhibitors [<a href="#CR22" rid="CR22" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807590">22</a>, <a href="#CR23" rid="CR23" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845252178">23</a>]. This protein has more than 60% of variant positions. We first aligned 24,155 amino acid sequences of the HIV protease. From this alignment, we determined all the couples of positions that were statistically never found mutated together, that we called SL and focused on the SL set, which are accessible to the solvent, and not too far apart spatially. We report here that our method has yielded 3 targets of respectively 4, 5 and 7 amino acids. Unlike currently documented drug targets, which mutate and escape drug treatments, these targets should be conserved, otherwise viral replicativity would suffer, impairing viral pathogenicity. More generally, this process can of course be used against other HIV proteins, other RNA viruses, or any highly variable agents.</p></div><div id="Sec2" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec2title">Results</h2><div id="Sec3" class="sec sec-first"><h3 id="Sec3title">Graph of the accessible and spatially close synthetic lethal clusters</h3><p id="__p11" class="p p-first">The first step is to define which couples of protease positions are synthetic lethal. To do so, we analyzed, from patients, 24,155 protease amino acid sequences of HIV-1 subtype B. Some patients had been previously treated with antiviral drugs, and some never, so the pool of sequences more appropriately represents the actual viral diversity. We kept all the sequences in one same set for four different reasons. Firstly, an untreated patient can get a viral sequence - possibly highly mutated - from a treated patient. Secondly, treatment is a selection pressure but other pressures can select other mutations appearing in both treated and untreated sets. Thirdly, our dataset can be enriched with plenty of mutations from unknown patients with unknown treatment histories. Finally, we wanted to create a tool that is robust enough to be used on other RNA virus databases that are less documented than HIV. When sequences occurred in multiple copies in the sequences collection, we kept all these redundant copies, assuming redundancy may reflect biological fitness (mostly identical copies from different patients, rather than multiple samples from the same patient). We did not use clonal data because it is less informative: not enough sequences, and not mutated enough. These 24,155 sequences were aligned. From this alignment, we found 25 positions that display changes in less than 0,3% of the sequences. We called those positions "invariants". Ceccherini-Silberstein <em>et al</em>. [<a href="#CR10" rid="CR10" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807575">10</a>], who defined invariant positions as displaying changes in less than 1% of the sequences, found 46 of those positions. All our 25 invariant positions were totally included in the Ceccherini-Silberstein invariant set of protease inhibitor (PI) treated patients. Stanford university HIV drug resistance database [<a href="#CR13" rid="CR13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807582">13</a>] described 36 positions represented in less than 0.5% of the HIV subtype B sequences from PI treated patients. Our 25 invariant positions are also all included in this group. The invariants positions were then set aside momentarily; and we compared the 74 variant positions in pairs (2,701 couples).</p><p id="__p12">To detect the SL couples in these 74, we first examined the distribution of the p-values of the &#x003c7;<sup>2</sup> test associated to each of these couples. Using a 0.5% False Discovery Rate (FDR) threshold, we identified 290 synthetic lethal couples (10.7%). These 290 couples span 70 protease positions out of the 74. The 4 remaining positions are not represented in these couples. We named "total SLs" the graph made of 70 nodes representing the 70 protease positions, and 290 edges representing the 290 relations "is co-lethal with" linking the synthetic lethal positions (data not shown).</p><p id="__p13">Three other teams have used different methods (information theory [<a href="#CR20" rid="CR20" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807579">20</a>], chi<sup>2</sup> studies [<a href="#CR19" rid="CR19" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807600">19</a>] Bayesian networks [<a href="#CR24" rid="CR24" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807561">24</a>]) to identify couples of HIV protease co-evolved positions. Amongst other results, they all found few synthetic lethal couples, around 15. Although unlike other teams, we did not discriminate the proteases from treated versus non-treated patients when collecting our initial lot of sequences, all these SL couples are included in our 290 SL couples and none of them are included in our SL sets. Our method therefore enables us to find the 15 couples already described by other teams using other methods.</p><p id="__p14">The distances between the two positions of each couple were calculated using the 3D protease structure PDB ID:1HSG [<a href="#CR25" rid="CR25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807571">25</a>]. The resulting distance graph was then superimposed to the "total SLs" graph. To be accessible by a putative drug, amino acids should fulfill two preconditions: to be spatially close enough to possibly form a pocket structure, and to be solvent-accessible (on the outside of the protein). Thus we chose to retain only the clusters of close positions, by only keeping the edges that indicate less than 10 Angstr&#x000f6;m of distance between two nodes. This resulted is a drastically reduced graph, of "spatially close SLs", shown Figure <a href="/pmc/articles/PMC2898770/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure1,</span></span><span>1</span></a>, going from 290 nodes to 48.</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig1" co-legend-rid="lgnd_Fig1"><a href="/pmc/articles/PMC2898770/figure/Fig1/" target="figure" rid-figpopup="Fig1" rid-ob="ob-Fig1"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139967163708016" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 13062_2010_Article_223_Fig1_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 13062_2010_Article_223_Fig1_HTML.jpg" src="/pmc/articles/PMC2898770/bin/13062_2010_Article_223_Fig1_HTML.jpg" /></div><div id="largeobj_idm139967163708016" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2898770/figure/Fig1/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig1"><div><a class="figpopup" href="/pmc/articles/PMC2898770/figure/Fig1/" target="figure" rid-figpopup="Fig1" rid-ob="ob-Fig1">Figure 1</a></div><!--caption a7--><div class="caption"><p id="__p15"><strong>Spatially close SLs</strong>. The whole graph represents the "spatially close SLs". The blue-shaded ovals, represents only the "accessible, spatially close SLs". Each oval contains the amino acid (one-letter codename) found in the HIV-1 protease ancestral sequence, followed by its position in this sequence. The accessible residues are all shaded in blue. The black edges linking the nodes mean "is co-lethal with and is within 10 Angstr&#x000f6;m from". The four orange, boxed amino acids (N37, P39, K41, D60) are the locked targets jointly called SG flap. The three red, boxed amino acids (H69, K70, I72) are the locked targets called SG canti. The two yellow, boxed amino acids (L10, T12) are the locked targets called SG fulc1 and the two yellow double-boxed amino acids (K14, L19) are the locked targets called SG fulc2. SG fulc1 plus SG fulc2 are called all together SG fulc. The graph was built with Graphviz software.</p></div></div></div><p id="__p16" class="p p-last">From the "spatially close SLs" graph, we selected the solvent accessible positions. (shown Figure <a href="/pmc/articles/PMC2898770/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure1</span></span><span>1</span></a> as the 20 shaded ovals). Visibly, only 4 clusters contained interlinked exposed positions, boxed in Figure <a href="/pmc/articles/PMC2898770/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure1,</span></span><span>1</span></a>, encompassing 11 nodes (shown as colored, orange red and yellow ovals) and 7 edges (black continuous lines). These are 4 separate, intra-connected subgraphs (or SG). These 4 SL sets are referred to as SG-flap (4 nodes, shown as orange ovals), SG-canti (3 nodes, red), SG-fulc1 (2 nodes, yellow) and SG-fulc2 (2 nodes, yellow). The combination of SG-fulc1 plus SG-fulc2 is named SG-fulc. The names were given retrospectively, as reminders of 3 specific regions of the protease 3D structure [<a href="#CR26" rid="CR26" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845252183">26</a>, <a href="#CR27" rid="CR27" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807565">27</a>]. Namely, SG-flap includes 3 positions found in the protease flaps. SG-canti includes positions found in the protease cantilever. And all positions of SG-fulc are in the protease fulcrum. No subgraph is part of the catalytic site [<a href="#CR28" rid="CR28" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807563">28</a>]. The 4 clusters we identified can now be complemented by their neighboring, accessible, invariants.</p></div><div id="Sec4" class="sec"><h3 id="Sec4title">Extending the SL sets: the flaps and cantilever</h3><p id="__p17" class="p p-first">For an anti-protease drug to be active, its docking must block a vital protease function. To compromise viral escape, it should dock on an invariant position or on an SL set. As described in Materials and Methods, we kept the invariant positions aside, as obviously lethal, when searching for synthetic lethals. But invariant positions are of course prime target candidates for the docking of an antiviral agent with limited escape possibilities. So we added all the invariant positions (shown as green rectangles shaded in blue on Figure <a href="/pmc/articles/PMC2898770/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure2)</span></span><span>2</span></a>) that are accessible and close, to the 4 locked sets (shown as ovals on Figure <a href="/pmc/articles/PMC2898770/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure2</span></span><span>2</span></a>).</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig2" co-legend-rid="lgnd_Fig2"><a href="/pmc/articles/PMC2898770/figure/Fig2/" target="figure" rid-figpopup="Fig2" rid-ob="ob-Fig2"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139967164594752" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 13062_2010_Article_223_Fig2_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 13062_2010_Article_223_Fig2_HTML.jpg" src="/pmc/articles/PMC2898770/bin/13062_2010_Article_223_Fig2_HTML.jpg" /></div><div id="largeobj_idm139967164594752" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2898770/figure/Fig2/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig2"><div><a class="figpopup" href="/pmc/articles/PMC2898770/figure/Fig2/" target="figure" rid-figpopup="Fig2" rid-ob="ob-Fig2">Figure 2</a></div><!--caption a7--><div class="caption"><p id="__p18"><strong>locked targets (accessible, spatially close locked sets)</strong>. All nodes shown here are accessible and spatially close amino acids The nodes in ovals are the accessible synthetic lethals which were shaded in blue on Figure 1, boxed with the same colour codes and linked by black edges. Each black edge means "is co-lethal with, and within 10 Angstr&#x000f6;m from". The corresponding p-value is shown above each edge. Invariant amino acids are boxed in green, linked by dotted green edges meaning "is within 10 Angstr&#x000f6;m from". All the nodes are shaded in blue because they are all accessible. Each invariant is also linked to all the other nodes by implicit edges, not shown, for the sake of clarity. The locked target represented subgraph "a" is called SGI flap (orange+green) The locked target represented subgraph "b" is called SGI canti (red+green) The locked target represented subgraph "c" is called SGI fulc (yellow+green) The graph was built using the Graphviz software.</p></div></div></div><p id="__p19">By the addition of invariants, we obtained 4 locked sets. But how much less escape-prone, how much more "locked? To quantify this, and rank graphs in terms of how closer to a maximal clique they were brought, we defined a connectivity coefficient, C, in Materials and Methods. C varies between 0, for a graph with no edges, and 1, for a graph where all the possible edges between nodes are present, i.e. a maximal clique. The closer C is to 1, the least escape-prone the group is.</p><p id="__p20">The full Figure <a href="/pmc/articles/PMC2898770/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure2</span></span><span>2</span></a> graph has 16 nodes and 72 edges (7 in black plus 65 implicit edges) linking each invariant position to all the others. For the sake of clarity only the 15 implicit links within a 10 Angstr&#x000f6;m distance are represented (as dotted green lines). SG-flap is now included in a larger connected subgraph named SGI-flap (7 nodes/18 edges including 3 in black, 10 in dotted lines, and 5 implicit edges Figure <a href="/pmc/articles/PMC2898770/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span>2.a</span></a>). The connectivity coefficient is increased from C<sub>SG-flap</sub> = 0.5 to C\'<sub>SGI-flap</sub> = 0.71. SGI-flap has 3 invariant amino acids, out of which 2 (G40, W42) are within 10 Angstr&#x000f6;m of each other, G40 is within 10 Angstr&#x000f6;m of the whole SG-flap residues and W42 is within 10 Angstr&#x000f6;m of (P39, K41, D60) from SG-flap residues. The whole SGI-flap set is an interesting result since its amino acids (N37, P39, G40, K41, W42, P44, D60) are all accessible, can\'t all freely mutate without damaging replicativity, and are close enough in space to imagine designing a single drug to target several of them. Figure <a href="/pmc/articles/PMC2898770/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure3a</span></span><span>3a</span></a> shows these amino acids on the dimerized 3D structure, using the same color codes as Figure <a href="/pmc/articles/PMC2898770/figure/Fig1/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig1" rid-ob="ob-Fig1" co-legend-rid="lgnd_Fig1"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure1</span></span><span>1</span></a> and <a href="/pmc/articles/PMC2898770/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -1.5em;">and2:</span></span><span>2</span></a>: four orange SLs and three green invariants. It is important to note here that each of these 7 positions does bear indispensable viral functions, namely:</p><!--fig ft0--><!--fig mode=article f1--><div class="fig iconblock whole_rhythm clearfix" id="Fig3" co-legend-rid="lgnd_Fig3"><a href="/pmc/articles/PMC2898770/figure/Fig3/" target="figure" rid-figpopup="Fig3" rid-ob="ob-Fig3"><!--fig/graphic|fig/alternatives/graphic mode="anchored" m1--><div data-largeobj="" data-largeobj-link-rid="largeobj_idm139967174739264" class="figure"><img class="fig-image" alt="An external file that holds a picture, illustration, etc.&#10;Object name is 13062_2010_Article_223_Fig3_HTML.jpg" title="An external file that holds a picture, illustration, etc.&#10;Object name is 13062_2010_Article_223_Fig3_HTML.jpg" src="/pmc/articles/PMC2898770/bin/13062_2010_Article_223_Fig3_HTML.jpg" /></div><div id="largeobj_idm139967174739264" class="largeobj-link align_right" style="display: none"><a target="object" href="/pmc/articles/PMC2898770/figure/Fig3/?report=objectonly">Open in a separate window</a></div></a><div class="icnblk_cntnt" id="lgnd_Fig3"><div><a class="figpopup" href="/pmc/articles/PMC2898770/figure/Fig3/" target="figure" rid-figpopup="Fig3" rid-ob="ob-Fig3">Figure 3</a></div><!--caption a7--><div class="caption"><p id="__p21"><strong>3D view of the locked targets</strong>. 3D representation of the HIV-1 homodimer (1HSG) protease. Same colour codes as Figures 1 and 2. a: SGI flap (4 orange SLs + 3 green invariants) b: SGI flap + SGI canti (2 red SLs + 1 green invariant) c: SGI fulc (2 yellow SLs + 1 green invariant) d: SGI fulc + SGI canti (4 yellow SLs + 1 green invariant) The 3D molecules were built by pymol software.</p></div></div></div><p id="__p22" class="p p-last">\n</p><ul class="unordered" style="list-style-type:disc"><!--\nlist-behavior=unordered\nprefix-word=\nmark-type=disc\nmax-label-size=0\n--><li><p id="__p23">Mutation in position 40 provokes a total loss of the protease activity [<a href="#CR29" rid="CR29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807595">29</a>].</p></li><li><p id="__p24">Mutation in either position 39 or 60 provokes a 50% drop in the protease activity [<a href="#CR29" rid="CR29" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807583">29</a>]</p></li><li><p id="__p25">Out of the 105 variants analyzed by Martinez et al. [<a href="#CR30" rid="CR30" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807557">30</a>], those with a mutation in position 37 display in average a 50% drop in the protease activity vs. wild type. Double mutants in positions 37 and 39 show a 75% drop vs. wild type, consistent with the possibility positions 37 and 39 might be SLs.</p></li><li><p id="__p26">Position 42 seems correlated to the flaps opening, and positions 39, 40 and 44 are very flexible, and positively required for the flaps to open [<a href="#CR31" rid="CR31" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807556">31</a>].</p></li><li><p id="__p27">Double mutants on K70E and R41T replicate poorly [<a href="#CR32" rid="CR32" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807554">32</a>]; an important piece of information for us since we report these 2 positions are SL (cf next paragraph).</p></li></ul><p>\n</p></div><div id="Sec5" class="sec"><h3 id="Sec5title">Extending the SL sets: the cantilever and fulcrum</h3><p id="__p28" class="p p-first-last">A look at SG-fulc yields complementary target recommendations. On SG-fulc, amino acid L10 is interesting because it is linked to the 3 other SLs (T12, K14, L19) as well as to invariant E21. The latter is close to all SG-fulc positions. T12 happens to be less than 10 Angstr&#x000f6;m (not shown) from the other 4. Furthermore, if distance is not taken in account, the amino acids (L10, K14, L19) are a maximal clique, so at most one may be found mutated. Overall, we identify a cluster of 5 amino acids with a connectivity coefficient of C\'<sub>SGI-fulc</sub> = 0.8, which are all close and amongst which at most two may freely mutate. This set, (L10, T12, K14, L19, E21), called SGI-fulc, is therefore a good target for a putative drug (Figure <a href="/pmc/articles/PMC2898770/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3.5em;">(Figure3c).</span></span><span>3c</span></a>). It is interesting to note that position 10 can have a secondary mutation conferring resistance [<a href="#CR33" rid="CR33" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807560">33</a>] and that mutations in position 12 occur more often in treated patients than in drug-naive patients [<a href="#CR34" rid="CR34" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807568">34</a>].</p></div><div id="Sec6" class="sec sec-last"><h3 id="Sec6title">Are the locked targets we described actually druggable pockets?</h3><p id="__p29" class="p p-first-last">We studied this using Q-siteFinder, a software program from the University of Leeds [<a href="#CR35" rid="CR35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807564">35</a>]. Q-siteFinder takes a 3D structure input and outputs its top 10 ligand-binding sites. Two out of the 10 ligand-binding sites in the protease overlap 2 of our locked targets (SGI-flap and SGI-fulc). Five out of seven positions in SGI-flap (39, 40, 41, 42, 60) are in the pocket of one of the 10 sites defined by Q-siteFinder (39, 40, 41, 42, 43, 58, 59, 60, 61, 62). Three out of five positions in SGI-fulc (12, 14, 19) are in the pocket of one of the 10 sites defined by Q-siteFinder (12, 13, 14, 19, 65, 66, 67, 68).</p></div></div><div id="Sec7" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec7title">Discussion</h2><p id="__p30" class="p p-first">All the amino acids in the first locked target (subgraph SGI-flap on Figure <a href="/pmc/articles/PMC2898770/figure/Fig3/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig3" rid-ob="ob-Fig3" co-legend-rid="lgnd_Fig3"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure3a)</span></span><span>3a</span></a>) are part of the protease flaps\' external loop. The flaps being mobile structures [<a href="#CR36" rid="CR36" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845252182">36</a>] that open out to let the substrate pass, one can imagine that a molecule drug-designed to bind the external loop of the protease flaps could block their mobility, therefore keeping the protease from processing its substrate. This idea was also developed by Perryman <em>et al</em>. using molecular dynamics [<a href="#CR37" rid="CR37" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807574">37</a>]: they also proposed to affect the flaps\' mobility. Our approach is in agreement with theirs, and we believe this group to be a very good candidate for future drug targeting.</p><p id="__p31">The method described in this manuscript enables us to define which amino-acids would be the most adequate drug targets to limit or avoid escape. But this method does not tell us whether these amino-acids define an actually druggable pocket. To check that, we used the Q-siteFinder software [<a href="#CR35" rid="CR35" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807567">35</a>], which takes the 3D structure of a protein as input, and outputs its ligand-binding sites. Out of the 3 SL locked targets we describe, 2 (SGI-flap and SGI-fulc) closely overlap two sites revealed by Q-siteFinder for the HIV protease, on respectively 5/7 and 3/5 positions. This result suggests our SL locked targets SGI-flap and SGI-fulc actually are druggable pockets.</p><p id="__p32">Since all our results use the "ancestral sequence" as a starting point, a relevant methodology control would be to check whether our above results stand if another acceptable starting point sequence is used. So we used the same method with the historical reference in medical studies, the HIVLAICG sequence [<a href="#CR38" rid="CR38" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807596">38</a>] (see methods), instead of the "ancestral sequence". The results are a smaller graph (not shown), equal to Figure <a href="/pmc/articles/PMC2898770/figure/Fig2/" target="figure" class="fig-table-link figpopup" rid-figpopup="Fig2" rid-ob="ob-Fig2" co-legend-rid="lgnd_Fig2"><span style="position: relative;text-decoration:none;">&#x200B;<span class="figpopup-sensitive-area" style="left: -3em;">Figure2</span></span><span>2</span></a> subgraphs SG-canti and SG-fulc plus 2 amino acids, (E34, E35). We believe both approaches are complementary and support each other, as mutual controls, since our recommendation to target SG-canti + SG-fulc is conserved to a great extent.</p><p id="__p33">From a general standpoint, it seems obvious that the different branches of one same phylogenetic tree can have their specific, own synthetic lethals. These synthetic lethals should not be mixed, since they\'re only usable targets in their relevant phylogenetic branch. In the case of HIV-1, they are three main branches are groups M, N and O. The branch of sub-group M is further divided in 7 sub-groups, including sub-group B. We choose to work on sub-group B because it has the more published sequences (over 20,000 for the protease) and mutations. Although there is no simple algorithm today to build a tree from tens of thousands of sequences, it would be interesting to study the phylogenic tree of our pool of sequences in parallel with our synthetic lethality study. However from an evolutionary point of view, we believe that the positive co-evolution of two sites (both positions always mutate together) is not the same issue as exclusive co-evolution (both positions can mutate but never together) Indeed, when examining the propagation of 2 mutated positions in a tree, two situations can be distinguished: either they are co-present in the majority of the sub-trees, which tends to indicate noise (since there is no segregation); or they are co-present only in the leaves of one part of the tree, which tends to indicate true co-evolution. Inversely, when studying a case of exclusive co-evolution, only one of these two situations is possible. Indeed, by definition of synthetic lethals, both mutations cannot be part of the same sub-tree since their co-presence is lethal. So the tree resulting from this situation is impossible to analyze, since one should analyze all the sub-trees in order to find the missing branches - which corresponds to the statistical study we conducted here.</p><p id="__p34">Our method treats variation in all positions as bi-allelic (mutated versus non-mutated genotype). Arguably, it would seem more informative to take into account the actual amino-acid changes. This would entail choosing a score matrix - most score matrixes do take into account the physico-chemical specificity of each amino-acid so as to decide whether the mutated one is similar or not to the initial one. But the mutations involved in the resistance to anti-protease drugs do not follow the same rules. Therefore we do not think using an existing score matrix of the Blosum or Pam type would be more informative.</p><p id="__p35">Finally, the fact a synthetic lethal co-mutation is never observed statistically does not mean such a co-mutation is completely impossible, hence our use of the expression "potential SLs" in cases with no experimental replication data. Our results indeed include cases where synthetic lethals were actually mutated (although this occurred in less 0.02%- 0.5% of the sequences, data not shown). So if these sequences truly represent replicative viruses, as opposed to unfiltered artifacts, then there is a risk that blocking some synthetic lethal couple with a new drug could create a selection bottleneck [<a href="#CR39" rid="CR39" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807580">39</a>, <a href="#CR40" rid="CR40" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807581">40</a>], forcing viral evolution towards more resistant strains. If such new escape mutants were to appear, they should carefully be monitored by sequencing at least their synthetic lethal positions, as a first step in further refining the antiviral strategy.</p><p id="__p36" class="p p-last">In any case, our method has the advantage to indicate the comprehensive list of all possible protease locked targets, the best targets to minimize or eliminate viral escape. Even if locked-set-designed anti-viral drugs were to somehow elicit escape mutants, the other (non-locked) amino acids would remain wrong targets, since viral escape seems nearly guaranteed with them: the corresponding multi-mutant HIVs are already in nature and their sequences in worldwide databanks.</p></div><div id="Sec8" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec8title">Conclusions</h2><p id="__p37" class="p p-first">The constant rise of drug resistant RNA viruses is a reason to start looking for therapeutic strategies that minimize or eliminate viral escape. We described here a method to identify targets that may be involved in essential viral functions. These are what we call locked targets: spatially close, accessible viral invariant positions and/or potential synthetic lethals (SLs are groups of survivable mutations which are lethal whenever any two co-occur). Due to these two features, vital function and invariance, these targets are unique in that they might minimize or prevent viral escape. Our application to the HIV protease yielded 3 locked targets that are accessible, compact enough to possibly dock a drug, and are all outside of the enzyme\'s active site; whereas to date, all 9 existing anti-protease drugs were competitive inhibitors that bind the active site. The first locked target we closed in on is made of 7 amino acids positioned between the protease flaps and cantilever. The second locked target we detected is made of 5 amino acids in the protease fulcrum. The third locked target is composed of 4 amino acids located in the protease cantilever region. These three locked targets altogether contain 16 protease amino acid positions. Biological evidence regarding 10 positions out of these 16, provided in the Results section supports that those 3 locked targets are strategic drug targets. This because it seems a virus cannot easily mutate these targets to escape, as our statistics significantly exclude free co-mutations within those targets. While our method made no a priori assumptions on the positions or sequence sets, it revealed locked targets that bear essential biologic functions, which validates the starting hypothesis linking SLs to essential biological functions.</p><p id="__p38">We believe this method can be used against any variable protein, for identification of the best locked targets.</p><p id="__p39" class="p p-last">Obviously, the approach described here can be used for the other HIV-1 [<a href="#CR41" rid="CR41" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807585">41</a>] and HIV-2 genes, but also for other viruses such as HCV [<a href="#CR42" rid="CR42" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845252177">42</a>], SARS-coV or influenza [<a href="#CR43" rid="CR43" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845252179">43</a>], or indeed for any quickly variable protein sequence. The large sequence banks needed for the statistics exist already, or can expand quickly due to the speed improvements in mass sequencing technology.</p></div><div id="Sec9" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec9title">Methods</h2><div id="Sec10" class="sec sec-first"><h3 id="Sec10title">Alignment of the sequences</h3><p id="__p40" class="p p-first">The pol gene codes for three proteins: the protease, the reverse transcriptase (RT) and the integrase, containing respectively 99, 560 and 288 amino acids.</p><p id="__p41">We pooled all of the amino acid sequences, whole or partial, of subtype B HIV-1 Pol from three databases: SwissProt, Los Alamos National Library [<a href="#CR44" rid="CR44" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807569">44</a>] and Stanford University HIV Drug Resistance Database [<a href="#CR13" rid="CR13" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807566">13</a>]. We thus collected over 70,000 Pol sequences from patients that are treated, non treated, or of unknown treatment history.</p><p id="__p42">Using a reference amino acid alignment of 438 HIV-1 protease downloaded from the Los Alamos National Library [<a href="#CR45" rid="CR45" class=" bibr popnode">45</a>], we built a profile with HMMER [<a href="#CR46" rid="CR46" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807570">46</a>] package using hmmbuild and hmmcalibrate function.</p><p id="__p43">Out of these 70,000 sequences, we first only kept those having at least 4 out of the 6 C-terminal protease motif (PQVTLW), or at least 4 out of the 6 N-terminal protease motif (GCTLNF), or both. This new set of over 20,000 sequences was then aligned on the abovementioned profile. The resulting alignment was used in order to create a new accurate profile for the alignment of small sequences. We then collected, from the initial 70,000 set, the partial sequences of 10 amino acids or more that had neither C-terminal nor N-terminal motif, but had at least 60% identity with the new profile. These partial sequences were then aligned on the new accurate profile. From this final alignment, we removed the 5 sequences that showed insertions.</p><p id="__p44" class="p p-last">We obtained one set of 24,155 protease sequences. Amongst the protease sequences, 11,206 sequences are represented only once, and the most frequent sequence was represented 257 times. 21,766 sequences are full length (contain the 99 positions of the protease).</p></div><div id="Sec11" class="sec"><h3 id="Sec11title">Choice of a reference sequence</h3><p id="__p45" class="p p-first">In order to label positions as "mutated" and "wild type", we needed a reference sequence [<a href="#CR47" rid="CR47" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807586">47</a>]. We first computed the consensus of our 24,155 protease sequences. But when we attempted to use it as our reference sequence, it misleadingly labeled as wild type some extremely frequent mutations. So we discarded that choice for a reference. The historical reference in medical studies HIVLAICG [GenBank:<a id="__tag_844807609" class="tag_hotlink" href="/nuccore/K02013" ref="/nuccore/K02013"><span class="tag-json" style="display:none">{"type":"entrez-nucleotide","attrs":{"text":"K02013","term_id":"326417","term_text":"K02013"}}</span>K02013</a>] [<a href="#CR38" rid="CR38" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807598">38</a>], was the first HIV-1 sequence ever published. HIVLAICG, though, is not the root of the phylogenic tree representing all the HIV-1 sequences. That root is the "ancestral sequence" [<a href="#CR48" rid="CR48" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807588">48</a>], phylogenetically computed from subtype B sequences [<a href="#CR45" rid="CR45" class=" bibr popnode">45</a>] and often the reference in biocomputing studies.</p><p id="__p46" class="p p-last">We observed that the sets of mutations defined vis-&#x000e0;-vis HIVLAICG or vis-&#x000e0;-vis the "ancestral sequence" were nearly identical (data not shown). Additionally, only two positions differ between these two sequences: positions 37 (N in the "ancestral sequence", versus S in HIVLAICG) and 41 (K versus R respectively). Overall, these arguments made us opt for the choice of the "ancestral sequence" as our reference. For control purposes, we also tried to use HIVLAICG as our reference in a separate experiment. It yielded very similar results.</p></div><div id="Sec12" class="sec"><h3 id="Sec12title">Identification of the potential synthetic lethal couples</h3><p id="__p47" class="p p-first">Our algorithm proceeded as follows on the alignment obtained. For each of the 24,155 protein sequences, the first position was compared to the first position of the reference sequence, to determine whether it was mutated. Each position mutated vis-&#x000e0;-vis the reference was recoded as 0 and each conserved one as 1. The same process was iterated for the second position, and so on until the end of the sequence. Thus, each sequence was recoded into a series of 0 and 1. Then we got a "24,155 &#x000d7; 99" matrix which each box containing either a 0 or a 1.</p><p id="__p48">To avoid mistaking "sequencing errors" for "mutations" in actually invariant amino acid positions, we set aside all the positions that display changes in less than 0.3% of the sequences. This cutoff of 0.3% was chosen here because it is the percentage of mutations we measured within three amino acids around the active site throughout our database. Using this threshold, we found 25 positions that display changes in less than 0.3% of the sequences. We refer to them as "invariants".</p><p id="__p49">We focused on the 74 other positions, in a "24,155 &#x000d7; 74" matrix. We chose a &#x003c7;<sup>2</sup> test to evaluate the mutual independence of positions in order to extract from this set the couples of potential synthetic lethality. We compared in pairs all these 74 positions (74 columns of the first matrix), noting the result in 2,701 (74*73/2) "2 &#x000d7; 2" matrixes. Each of these "2 &#x000d7; 2" matrixes (contingency table) contained four elements: the number of (mutated mutated) represented as (0 0) in the 2 columns that we are comparing in the first matrix, the number of the (non-mutated non-mutated) as (1 1), the number of the (mutated non-mutated) as (0 1) and the number of the (non-mutated mutated) as (1 0). In the null hypothesis that both positions are independent, using those 4 numbers, we performed 2,701 times, a one-degree-of-freedom &#x003c7;<sup>2</sup> test, and the associated p-values were calculated for each of the couples of positions. Since we did multiple tests, in order to compare these p-value results and decide whether the results were significant or not, we studied the distribution of the p-values. Then using Benjamini-Hochberg\'s [<a href="#CR49" rid="CR49" class=" bibr popnode">49</a>] and Storey [<a href="#CR50" rid="CR50" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845252180">50</a>] methods, we computed the false discovery rate (FDR) associated to the different p-values.</p><p id="__p50">For each of the 100 alpha risk classes varying between 0 and 1 (each alpha risk class representing 1%), we computed the counts of the associated p-values and then built the associated histogram. Finally, the FDR associated to an alpha risk of 0.05 was computed with the following formula:</p><div class="disp-formula" id="Equ1"><div class="f"><img src="/pmc/articles/PMC2898770/bin/13062_2010_Article_223_Equ1_HTML.gif" class="eq-image" alt="equation image" title="equation image" /></div><div class="l">1</div></div><p></p><p id="__p51">with</p><div class="disp-formula" id="Equ2"><div class="f"><img src="/pmc/articles/PMC2898770/bin/13062_2010_Article_223_Equ2_HTML.gif" class="eq-image" alt="equation image" title="equation image" /></div><div class="l">2</div></div><p></p><p id="__p52">where n is the total number of p-values calculated, nb (&#x003b1;) the class count associated to a. Finally, we kept only the couples for which the p-value had an FDR lower than 0.05. The positions of these couples are therefore all statistically dependent in pairs.</p><p id="__p53" class="p p-last">Out of all these statistically dependent couples, in order to define synthetic lethals, we focused on the positions where the observed number of mutated/non mutated and non mutated/mutated couples was greater than the theoretically expected number if the two positions were mutating independently. This singled out couples of positions that statistically mutate less often together than what would be expected from a random behavior. This statistical dependency between positions is referred to below as the relation "seems synthetic lethal with", or, indifferently, "seems co-lethal with". The couples will be called SLs in the following, keeping in mind that formally they should be called "potential SLs" until biological data demonstrates actual co-lethality.</p></div><div id="Sec13" class="sec"><h3 id="Sec13title">Identification of the accessible positions</h3><p id="__p54" class="p p-first-last">In order to define the accessibility of the amino acids to some putative external ligand - with a future drug in mind, using the 3D protease structure PDB ID:1HSG [<a href="#CR25" rid="CR25" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807594">25</a>], we computed the surface accessible to the solvent, using the ASA software [<a href="#CR51" rid="CR51" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_844807578">51</a>] available at RPBS [<a href="#CR52" rid="CR52" class=" bibr popnode tag_hotlink tag_tooltip" id="__tag_845252181">52</a>], and considered "accessible" all amino acids with an accessibility threshold greater than 25%.</p></div><div id="Sec14" class="sec sec-last"><h3 id="Sec14title">Identification of locked sets</h3><p id="__p55" class="p p-first">A set of elements (e.g. amino acids) linked by relations can be represented as a graph. The graph we designed for this study has one node for each protease amino acid position. The graph\'s edges bear the relation "is co-lethal with".</p><p id="__p56">Calling N the number of nodes in a graph, the minimal number of edges is A<sub>min</sub> = 0 and the maximal number of edges is <span id="IEq1"><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 13062_2010_Article_223_IEq1_HTML.gif" src="/pmc/articles/PMC2898770/bin/13062_2010_Article_223_IEq1_HTML.gif" class="equation" /></span>.</p><p id="__p57">When a graph reaches the maximum number of edges, i.e. when all its nodes are interlinked two by two, it is called a maximal clique. This property is important when screening SLs because within a maximal clique, at most one amino acid may mutate freely, any second mutation being lethal.</p><p id="__p58">To determine the maximal cliques contained in our graph, we used a program (Eric Coissac, personal communication).</p><p id="__p59">Most SL sets are not maximal cliques, but some SL sets are quite close to being maximal cliques. Then we wanted to determine the degree of connectivity of a graph.</p><p id="__p60">We defined C as <span id="IEq2"><img alt="An external file that holds a picture, illustration, etc.&#10;Object name is 13062_2010_Article_223_IEq2_HTML.gif" src="/pmc/articles/PMC2898770/bin/13062_2010_Article_223_IEq2_HTML.gif" class="equation" /></span> where A<sub>obs</sub> is the observed number of edges of the graph.</p><p id="__p61">The closer C is to 1, the closer the graph is to a maximal clique, the set being so locked only one mutation is possible without lethality. Inversely, a value close to 0 indicates that all the positions considered may mutate without any lethality, the set is not locked, nor even an SL set, but just a plain set of amino acid positions.</p><p id="__p62">Whenever a node is an invariant amino acid, it is by definition linked to all the other nodes. We indeed add invariants to SL sets in order to extend our targets into "locked sets". By "a locked set" we mean "an SL set plus all the invariant positions". Indeed, a set of positions containing invariant amino acids plus an SL set may be large enough a target for putative antiviral drugs. We call all these most conserved positions "locked" because they "can\'t escape" by freely mutating. Invariants are totally locked (no mutation is survivable), while SL sets are partially locked (some, but not all, mutation combinations are survivable).</p><p id="__p63">When n invariant nodes are added to a graph of m nodes already linked by A <sub>obs</sub> edges, then the new connectivity coefficient C\' is:</p><div class="disp-formula" id="Equ3"><div class="f"><img src="/pmc/articles/PMC2898770/bin/13062_2010_Article_223_Equ3_HTML.gif" class="eq-image" alt="equation image" title="equation image" /></div></div><p></p><p id="__p64" class="p p-last">The connectivity gained when invariants are added to an SL set is quantified by the increase from C to C\'.</p></div></div><div id="Sec15" class="tsec sec"><h2 class="head no_bottom_margin" id="Sec15title">Reviewers\' comments</h2><div id="Sec16" class="sec sec-first"><h3 id="Sec16title">Reviewer\'s report 1</h3><p id="__p65" class="p p-first-last">Reviewer 1: A.Mushegian, Stowers Institute, Kansas City, United States</p></div><div id="Sec17" class="sec"><h3 id="Sec17title">Reviewer\'s comment</h3><p id="__p66" class="p p-first">The manuscript by Brouillet and co-authors presents a simple, direct and, in my opinion, promising strategy towards computational selection of druggable targets, based on the inference of intramolecular synthetic lethal pairs of amino acid substitutions. It is clearly written, and I do not have any major concerns with the technical side of the work. However, additional explanation of the following would be helpful.</p><p id="__p67" class="p p-last">The authors present their reasons for including all the data, except for incomplete and suspected-erroneous sequences. These reasons are compelling enough to me, and yet I am wondering whether the data are biased in some way. Does the assignment of synthetic lethals change if the dataset is made non-redundant? If we sample from the total dataset repeatedly?</p></div><div id="Sec19" class="sec"><h3 id="Sec19title">Reviewer\'s comment</h3><p id="__p68" class="p p-first-last">A related issue is the application of the method to other molecules. The authors indicate that if there are not enough sequences (from another virus) in the databases, the new-generation sequencing methods may come to the rescue. But what should be sequenced, how many reads should be enough, and are there any properties of the sample that might predict the success of the approach?</p></div><div id="Sec21" class="sec"><h3 id="Sec21title">Reviewer\'s comment</h3><p id="__p69" class="p p-first">Perhaps some simulations, and repetition of the experiment on the historic data on HIV (what was the year, dataset, or sequencing strategy that for the first time made the synthetic-lethal pairs visible using the method) may provide some guidance?</p><p id="__p70" class="p p-last">I declare that I have no competing interests.</p></div><div id="Sec22" class="sec"><h3 id="Sec22title">Reviewer\'s report 2</h3><p id="__p71" class="p p-first-last">Reviewer 2: Shamil Sunyaev, Harvard Medical School, Boston, MA, United States</p></div><div id="Sec23" class="sec"><h3 id="Sec23title">Reviewer\'s comment</h3><p id="__p72" class="p p-first">This is an interesting manuscript on molecular evolution and structural analysis of the HIV protease. The goal of the study is to use co-evolution of amino acid pairs for proposing drug binding sites immune to mutational escape. Although the work is of interest, I have a few comments listed below.</p><p id="__p73" class="p p-last">The approach based on the contingency table analysis ignores phylogenetic structure of the dataset. This may lead to false-positive predictions of co-evolved residues. It is clear that the size of the dataset prevents any accurate phylogenetic analysis. However, it should be easier to verify that selected clusters cannot be explained by phylogeny and represent a real signal of co-evolution. At least, the manuscript would benefit from a detailed discussion of this point.</p></div><div id="Sec25" class="sec"><h3 id="Sec25title">Reviewer\'s comment</h3><p id="__p74" class="p p-first-last">It is unclear why does the method treat variation in all positions as bi-allelic (mutated or non-mutated genotype). It is possible that taking into account actual amino acid types would be more informative. Again, this point warrants at least a detailed discussion.</p></div><div id="Sec27" class="sec"><h3 id="Sec27title">Reviewer\'s comment</h3><p id="__p75" class="p p-first-last">The manuscript would benefit from the clarification of the main hypothesis. Why would a single mutation at the SL cluster be always insufficient for an efficient escape?</p></div><div id="Sec29" class="sec"><h3 id="Sec29title">Reviewer\'s comment</h3><p id="__p76" class="p p-first-last">The authors observe co-evolution rather than synthetic lethality. This result can be explained by a very moderate fitness loss rather than lethality. This is a serious complication for the anti-escape strategy. It would be great to discuss this issue.</p></div><div id="Sec31" class="sec"><h3 id="Sec31title">Reviewer\'s comment</h3><p id="__p77" class="p p-first-last">It is of interest that the majority of SL pairs are distant. Possibly, this warrants an additional discussion as well.</p></div><div id="Sec33" class="sec"><h3 id="Sec33title">Reviewer\'s report 3</h3><p id="__p78" class="p p-first-last">Reviewer 3: Claus Wilke, University of Texas, Center for Computational Biology and Institute for Cell and Molecular Biology, Austin, Texas, United States.</p></div><div id="Sec34" class="sec"><h3 id="Sec34title">Reviewer\'s commen</h3><p id="__p79" class="p p-first">The authors suggest a novel approach to developing drugs that HIV could not easily evolve resistance to: drugs that target multiple sites, all of which cannot jointly mutate. I think this is a valid concept in principle. The authors then proceed to identify sets of mutations that might be suitable drug targets, through an analysis of covariation in a large alignment of HIV sequences.</p><p id="__p80" class="p p-last">By and large, I find the paper a bit thin. The proposed sets of mutations are only candidates, there is no experimental verification showing that they truly cannot mutate together. There is also no demonstration that a drug could actually be made to act at the specific combination of sites proposed. On the upside, the authors are very forthcoming with the weaknesses of the study. They do not oversell their results.</p></div><div id="Sec36" class="sec"><h3 id="Sec36title">Reviewer\'s comment</h3><p id="__p81" class="p p-first-last">I have one major concern with the definition of synthetic lethals, though. The authors identify them on the basis of a test of association. The null hypothesis in this test is that the frequency with which both sites are mutated is the product of the frequencies with which individual sites are mutated. Any deviation from this null hypothesis, however small, can produce a significant result if the number of observations is sufficiently large. Thus, if site B is only slightly less likely to be mutated when site A has been mutated, the authors\' procedure would predict that A and B are a synthetic lethal pair, even though the fitness cost of mutating both A and B may be minute.</p></div><div id="Sec38" class="sec"><h3 id="Sec38title">Reviewer\'s comment</h3><p id="__p82" class="p p-first">It seems to me that a better way to define synthetic lethals is to search for pairs of sites that never mutate together, i.e., where the frequency of (1 1) pairs is below the threshold for sequencing errors of (.3%)^2. I suspect, though, that such pairs are exceedingly rare.</p><p id="__p83" class="p p-last">A second concern that I have with the method in the present paper is that it does not consider the effect of evolutionary history. It is well known that phylogenetic relationships can produce apparent non-independence of sites. Methods to control for this effect exist and could be used in place of the authors\' method, see e.g. Noivirt O, Eisenstein M, Horovitz A. (2005) Detection and reduction of evolutionary noise in correlated mutation analysis. Protein Eng. Des. Sel. 18, 247-253.</p></div><div id="Sec40" class="sec"><h3 id="Sec40title">Re-reviewer\'s report 3</h3><p id="__p84" class="p p-first-last">Reviewer 3: Claus Wilke, University of Texas, Center for Computational Biology and Institute for Cell and Molecular Biology, Austin, Texas, United States.</p></div><div id="Sec41" class="sec sec-last"><h3 id="Sec41title">Reviewer\'s comment</h3><p id="__p85" class="p p-first">The authors use the concept of co-lethality of mutations to identify possible drug targets in HIV. I have two major comments.</p><p id="__p86">1. I am concerned about the definition of synthetic lethals. The authors identify them on the basis of a test of association. The null hypothesis in this test is that the frequency with which both sites are mutated is the product of the frequencies with which individual sites are mutated. Any deviation from this null hypothesis, however small, can produce a significant result if the number of observations is sufficiently large. Thus, if site B is only slightly less likely to be mutated when site A has been mutated, the authors\' procedure would predict that A and B are a synthetic lethal pair, even though the fitness cost of mutating both A and B may be minute.</p><p id="__p87" class="p p-last">2. The method in the present paper does not control for the effect of evolutionary history. It is well known that phylogenetic relationships can produce apparent non-independence of sites. Methods to control for this effect exist and could be used in place of the authors\' method, see e.g. Noivirt O, Eisenstein M, Horovitz A. (2005) Detection and reduction of evolutionary noise in correlated mutation analysis. Protein Eng. Des. Sel. 18, 247-253. The authors argue that their data set is too large to control for phylogeny. That may be the case, but it doesn\'t alter the fact that the data set is likely confounded by phylogeny.</p></div></div><div id="idm139967165121728" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139967165121728title">Acknowledgements</h2><div class="sec"><p id="__p111">We thank "L\'atelier de bioinformatique" for being what it is, Eric Coissac for their software, Karl Forner for his help in statistics, Isabelle Gon&#x000e7;alves, Jo&#x000eb;l Pothier, Michaela Muller-Trutwin, Patrick Dechavanne and Reiner Veitia for critical reading of the manuscript and P. Le Chien for his encouragements since 1993. This work was done for Lou, 5 years old, who died of AIDS in 1997.</p></div></div><div id="idm139967170228496" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139967170228496title">Abbreviations</h2><div class="bk-sec"><div><table class="default-table glossary"><tbody><tr><td>HIV</td><td>Human immunodeficiency virus</td></tr><tr><td>AIDS</td><td>acquired immunodeficiency syndrome</td></tr><tr><td>SL</td><td>Synthetic lethality</td></tr><tr><td>HVC</td><td>Hepatitis C virus</td></tr><tr><td>SARS</td><td>Severe Acute Respiratory Syndrome</td></tr><tr><td>SARS-coV</td><td>Severe Acute Respiratory Syndrome CoronaVirus</td></tr><tr><td>FDR</td><td>False Discovery Rate</td></tr><tr><td>PI</td><td>Protease Inhibitor</td></tr><tr><td>RT</td><td>reverse transcriptase</td></tr><tr><td>PDB</td><td>Protein Data Bank</td></tr><tr><td>SG</td><td>Sub-Graph</td></tr><tr><td>SGI</td><td>Sub-Graph + Invariant</td></tr><tr><td>Fulc</td><td>Fulcrum</td></tr><tr><td>Canti</td><td>Cantilever</td></tr><tr><td>3D</td><td>Tridimensional</td></tr></tbody></table></div></div></div><div id="App1" class="tsec sec headless whole_rhythm"><!--/article/back/app-group/app/--><div id="Sec42" class="sec sec-first"><h3 id="Sec42title">Authors&#x02019; original submitted files for images</h3><p id="__p88" class="p p-first-last">Below are the links to the authors&#x02019; original submitted files for images.<span class="sup-box" id="MOESM1"><a href="/pmc/articles/PMC2898770/bin/13062_2010_223_MOESM1_ESM.pdf" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 1</a><sup>(116K, pdf)</sup></span><span class="sup-box" id="MOESM2"><a href="/pmc/articles/PMC2898770/bin/13062_2010_223_MOESM2_ESM.pdf" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 2</a><sup>(71K, pdf)</sup></span><span class="sup-box" id="MOESM3"><a href="/pmc/articles/PMC2898770/bin/13062_2010_223_MOESM3_ESM.pdf" data-ga-action="click_feat_suppl">Authors&#x02019; original file for figure 3</a><sup>(1.5M, pdf)</sup></span></p></div></div><div id="idm139967165318128" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139967165318128title">Footnotes</h2><!--back/fn-group--><div class="fm-sec half_rhythm small"><p class="fn sec" id="idm139967165318000"><p id="__p107" class="p p-first"><strong>Competing interests</strong></p><p id="__p108" class="p p-last">The authors have a financial interest in patent application, which cover some of the work described in the paper.</p></p><p class="fn sec" id="idm139967165123680"><p id="__p109" class="p p-first"><strong>Authors\' contributions</strong></p><p id="__p110" class="p p-last">SB Carried out the sequence alignment, identified the synthetic lethal couples and the locked sets, performed the statistical analysis, wrote the method section and helped to draft the manuscript; TV helped with study design, provided comments and feedback on draft manuscript and translated it into English; EO created the database and was involved in drafting the manuscript; LM provided help in statistical and SL couples analysis; AV carried out conception, design and coordination, analysis and interpretation of the SL couples and locked sets, wrote the draft manuscript and gave the final approval of the version to be published. All authors read and approved the final manuscript.</p></p></div></div><div id="idm139967162271856aff-info" class="tsec sec"><h2 class="head no_bottom_margin" id="idm139967162271856aff-infotitle">Contributor Information</h2><p><span class="fm-affl">Sophie Brouillet, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="rf.cmpu@telliuorb.eihpos" class="oemail">rf.cmpu@telliuorb.eihpos</a></span>.</p><p><span class="fm-affl">Thomas Valere, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.xobop@erelavt" class="oemail">moc.xobop@erelavt</a></span>.</p><p><span class="fm-affl">Emmanuelle Ollivier, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="rf.cmpu@reivillo.elleunamme" class="oemail">rf.cmpu@reivillo.elleunamme</a></span>.</p><p><span class="fm-affl">Laurent Marsan, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="moc.liamg@nasram.ual" class="oemail">moc.liamg@nasram.ual</a></span>.</p><p><span class="fm-affl">Anne Vanet, </span><span class="fm-affl"><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="rf.toredid-sirap-vinu@tenav.enna" class="oemail">rf.toredid-sirap-vinu@tenav.enna</a></span>.</p></div><div id="Bib1" class="tsec sec"><h2 class="head no_bottom_margin" id="Bib1title">References</h2><div class="ref-list-sec sec" id="reference-list"><div class="ref-cit-blk half_rhythm" id="CR1">1. <span class="element-citation">Shafer RW, Schapiro JM. HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. <span><span class="ref-journal">AIDS Rev. </span>2008;<span class="ref-vol">10</span>(2):67\xe2\x80\x9384.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2547476/">PMC free article</a>]</span> [<a href="/pubmed/18615118" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=AIDS+Rev&amp;title=HIV-1+drug+resistance+mutations:+an+updated+framework+for+the+second+decade+of+HAART&amp;author=RW+Shafer&amp;author=JM+Schapiro&amp;volume=10&amp;issue=2&amp;publication_year=2008&amp;pages=67-84&amp;pmid=18615118&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR2">2. <span class="element-citation">Enserink M. Drug resistance. A \'wimpy\' flu strain mysteriously turns scary. <span><span class="ref-journal">Science. </span>2009;<span class="ref-vol">323</span>(5918):1162\xe2\x80\x933. doi: 10.1126/science.323.5918.1162.</span> [<a href="/pubmed/19251605" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1126%2Fscience.323.5918.1162" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Drug+resistance.+A+\'wimpy\'+flu+strain+mysteriously+turns+scary&amp;author=M+Enserink&amp;volume=323&amp;issue=5918&amp;publication_year=2009&amp;pages=1162-3&amp;pmid=19251605&amp;doi=10.1126/science.323.5918.1162&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR3">3. <span class="element-citation">Ren J, Stammers DK. Structural basis for drug resistance mechanisms for non-nucleoside inhibitors of HIV reverse transcriptase. <span><span class="ref-journal">Virus Res. </span>2008;<span class="ref-vol">134</span>(1-2):157\xe2\x80\x9370. doi: 10.1016/j.virusres.2007.12.018.</span> [<a href="/pubmed/18313784" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.virusres.2007.12.018" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Virus+Res&amp;title=Structural+basis+for+drug+resistance+mechanisms+for+non-nucleoside+inhibitors+of+HIV+reverse+transcriptase&amp;author=J+Ren&amp;author=DK+Stammers&amp;volume=134&amp;issue=1-2&amp;publication_year=2008&amp;pages=157-70&amp;pmid=18313784&amp;doi=10.1016/j.virusres.2007.12.018&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR4">4. <span class="element-citation">Noronha G, Cao J, Chow C, Dneprovskaia E, Hwang L, Lohse D, Ching Mak C, McPherson A, Fine RM, Kang X, Klebansky B, Palanki MSS, Pathak VP, Renick J, Soll R, Zeng B. Targeting drug resistant mutations using novel binding interactions - Lessons learned from Abl-T315I and their implications in drug design. <span><span class="ref-journal">Frontiers in drug design &#x00026; discovery. </span>2007;<span class="ref-vol">3</span>:121\xe2\x80\x93144.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Frontiers+in+drug+design+&#x00026;+discovery&amp;title=Targeting+drug+resistant+mutations+using+novel+binding+interactions+-+Lessons+learned+from+Abl-T315I+and+their+implications+in+drug+design&amp;author=G+Noronha&amp;author=J+Cao&amp;author=C+Chow&amp;author=E+Dneprovskaia&amp;author=L+Hwang&amp;volume=3&amp;publication_year=2007&amp;pages=121-144&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR5">5. <span class="element-citation">Maggio ET, Shenderovich M, Kagan R, Goddette D, Ramnarayan K. Structural pharmacogenomics, drug resistance and the design of anti-infective super-drugs. <span><span class="ref-journal">Drug Discov Today. </span>2002;<span class="ref-vol">7</span>(24):1214\xe2\x80\x9320. doi: 10.1016/S1359-6446(02)02514-X.</span> [<a href="/pubmed/12547004" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS1359-6446(02)02514-X" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Drug+Discov+Today&amp;title=Structural+pharmacogenomics,+drug+resistance+and+the+design+of+anti-infective+super-drugs&amp;author=ET+Maggio&amp;author=M+Shenderovich&amp;author=R+Kagan&amp;author=D+Goddette&amp;author=K+Ramnarayan&amp;volume=7&amp;issue=24&amp;publication_year=2002&amp;pages=1214-20&amp;pmid=12547004&amp;doi=10.1016/S1359-6446(02)02514-X&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR6">6. <span class="element-citation">Ghosh AK, Chapsal BD, Weber IT, Mitsuya H. Design of HIV protease inhibitors targeting protein backbone: an effective strategy for combating drug resistance. <span><span class="ref-journal">Acc Chem Res. </span>2008;<span class="ref-vol">41</span>(1):78\xe2\x80\x9386. doi: 10.1021/ar7001232.</span> [<a href="/pubmed/17722874" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1021%2Far7001232" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Acc+Chem+Res&amp;title=Design+of+HIV+protease+inhibitors+targeting+protein+backbone:+an+effective+strategy+for+combating+drug+resistance&amp;author=AK+Ghosh&amp;author=BD+Chapsal&amp;author=IT+Weber&amp;author=H+Mitsuya&amp;volume=41&amp;issue=1&amp;publication_year=2008&amp;pages=78-86&amp;pmid=17722874&amp;doi=10.1021/ar7001232&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR7">7. <span class="element-citation">Broglia RA, Tiana G, Sutto L, Provasi D, Simona F. Design of HIV-1-PR inhibitors that do not create resistance: blocking the folding of single monomers. <span><span class="ref-journal">Protein Sci. </span>2005;<span class="ref-vol">14</span>(10):2668\xe2\x80\x9381. doi: 10.1110/ps.051670905.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2253289/">PMC free article</a>]</span> [<a href="/pubmed/16195553" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1110%2Fps.051670905" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Protein+Sci&amp;title=Design+of+HIV-1-PR+inhibitors+that+do+not+create+resistance:+blocking+the+folding+of+single+monomers&amp;author=RA+Broglia&amp;author=G+Tiana&amp;author=L+Sutto&amp;author=D+Provasi&amp;author=F+Simona&amp;volume=14&amp;issue=10&amp;publication_year=2005&amp;pages=2668-81&amp;pmid=16195553&amp;doi=10.1110/ps.051670905&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR8">8. <span class="element-citation">Foulkes JE, Prabu-Jeyabalan M, Cooper D, Henderson GJ, Harris J, Swanstrom R, Schiffer CA. Role of invariant Thr80 in human immunodeficiency virus type 1 protease structure, function, and viral infectivity. <span><span class="ref-journal">J Virol. </span>2006;<span class="ref-vol">80</span>(14):6906\xe2\x80\x9316. doi: 10.1128/JVI.01900-05.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1489026/">PMC free article</a>]</span> [<a href="/pubmed/16809296" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FJVI.01900-05" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Role+of+invariant+Thr80+in+human+immunodeficiency+virus+type+1+protease+structure,+function,+and+viral+infectivity&amp;author=JE+Foulkes&amp;author=M+Prabu-Jeyabalan&amp;author=D+Cooper&amp;author=GJ+Henderson&amp;author=J+Harris&amp;volume=80&amp;issue=14&amp;publication_year=2006&amp;pages=6906-16&amp;pmid=16809296&amp;doi=10.1128/JVI.01900-05&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR9">9. <span class="element-citation">Colman PM. A novel approach to antiviral therapy for influenza. <span><span class="ref-journal">J Antimicrob Chemother. </span>1999;<span class="ref-vol">44</span>(Suppl B):17\xe2\x80\x9322. doi: 10.1093/jac/44.suppl_2.17.</span> [<a href="/pubmed/10877458" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1093%2Fjac%2F44.suppl_2.17" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Antimicrob+Chemother&amp;title=A+novel+approach+to+antiviral+therapy+for+influenza&amp;author=PM+Colman&amp;volume=44&amp;issue=Suppl+B&amp;publication_year=1999&amp;pages=17-22&amp;pmid=10877458&amp;doi=10.1093/jac/44.suppl_2.17&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR10">10. <span class="element-citation">Ceccherini-Silberstein F, Erba F, Gago F, Bertoli A, Forbici F, Bellocchi MC, Gori C, D\'Arrigo R, Marcon L, Balotta C, Antinori A, Monforte AD, Perno CF. Identification of the minimal conserved structure of HIV-1 protease in the presence and absence of drug pressure. <span><span class="ref-journal">AIDS. </span>2004;<span class="ref-vol">18</span>(12):F11\xe2\x80\x939. doi: 10.1097/01.aids.0000131394.76221.02.</span> [<a href="/pubmed/15280771" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1097%2F01.aids.0000131394.76221.02" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=AIDS&amp;title=Identification+of+the+minimal+conserved+structure+of+HIV-1+protease+in+the+presence+and+absence+of+drug+pressure&amp;author=F+Ceccherini-Silberstein&amp;author=F+Erba&amp;author=F+Gago&amp;author=A+Bertoli&amp;author=F+Forbici&amp;volume=18&amp;issue=12&amp;publication_year=2004&amp;pages=F11-9&amp;pmid=15280771&amp;doi=10.1097/01.aids.0000131394.76221.02&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR11">11. <span class="element-citation">Ceccherini-Silberstein F, Gago F, Santoro M, Gori C, Svicher V, Rodr&#x000ed;guez-Barrios F, d\'Arrigo R, Ciccozzi M, Bertoli A, d\'Arminio Monforte A, Balzarini J, Antinori A, Perno CF. High sequence conservation of human immunodeficiency virus type 1 reverse transcriptase under drug pressure despite the continuous appearance of mutations. <span><span class="ref-journal">J Virol. </span>2005;<span class="ref-vol">79</span>(16):10718\xe2\x80\x9329. doi: 10.1128/JVI.79.16.10718-10729.2005.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1182657/">PMC free article</a>]</span> [<a href="/pubmed/16051864" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FJVI.79.16.10718-10729.2005" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=High+sequence+conservation+of+human+immunodeficiency+virus+type+1+reverse+transcriptase+under+drug+pressure+despite+the+continuous+appearance+of+mutations&amp;author=F+Ceccherini-Silberstein&amp;author=F+Gago&amp;author=M+Santoro&amp;author=C+Gori&amp;author=V+Svicher&amp;volume=79&amp;issue=16&amp;publication_year=2005&amp;pages=10718-29&amp;pmid=16051864&amp;doi=10.1128/JVI.79.16.10718-10729.2005&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR12">12. <span class="element-citation">Santoro MM, Bertoli A, Lorenzini P, Ceccherini-Silberstein F, Gianotti N, Mussini C, Torti C, Di Perri G, Barbarini G, Bini T, Melzi S, Caramello P, Maserati R, Narciso P, Micheli V, Antinori A, Perno CF, CARe Study Group  Two Different Patterns of Mutations are Involved in the Genotypic Resistance Score for Atazanavir Boosted Versus Unboosted by Ritonavir in Multiple Failing Patients. <span><span class="ref-journal">Infection. </span>2009;<span class="ref-vol">37</span>(3):233\xe2\x80\x9343. doi: 10.1007/s15010-008-8065-4.</span> [<a href="/pubmed/19169632" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1007%2Fs15010-008-8065-4" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Infection&amp;title=Two+Different+Patterns+of+Mutations+are+Involved+in+the+Genotypic+Resistance+Score+for+Atazanavir+Boosted+Versus+Unboosted+by+Ritonavir+in+Multiple+Failing+Patients&amp;author=MM+Santoro&amp;author=A+Bertoli&amp;author=P+Lorenzini&amp;author=F+Ceccherini-Silberstein&amp;author=N+Gianotti&amp;volume=37&amp;issue=3&amp;publication_year=2009&amp;pages=233-43&amp;pmid=19169632&amp;doi=10.1007/s15010-008-8065-4&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR13">13. <span class="element-citation">Shafer RW. Rationale and uses of a public HIV drug-resistance database. <span><span class="ref-journal">J Infect Dis. </span>2006;<span class="ref-vol">194</span>(Suppl 1):S51\xe2\x80\x938. doi: 10.1086/505356.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2614864/">PMC free article</a>]</span> [<a href="/pubmed/16921473" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1086%2F505356" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=Rationale+and+uses+of+a+public+HIV+drug-resistance+database&amp;author=RW+Shafer&amp;volume=194&amp;issue=Suppl+1&amp;publication_year=2006&amp;pages=S51-8&amp;pmid=16921473&amp;doi=10.1086/505356&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR14">14. <span class="element-citation">Lucchesi JC. Synthetic lethality and semi-lethality among functionally related mutants of Drosophila melanfgaster. <span><span class="ref-journal">Genetics. </span>1968;<span class="ref-vol">59</span>(1):37\xe2\x80\x9344.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1211931/">PMC free article</a>]</span> [<a href="/pubmed/5683639" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Genetics&amp;title=Synthetic+lethality+and+semi-lethality+among+functionally+related+mutants+of+Drosophila+melanfgaster&amp;author=JC+Lucchesi&amp;volume=59&amp;issue=1&amp;publication_year=1968&amp;pages=37-44&amp;pmid=5683639&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR15">15. <span class="element-citation">Kaiser C, Gimeno R, Shaywitz D.  In: <span class="ref-journal">The molecular and cellular biology of the yeast Saccharomyces.</span> Pringle J, Broach J, Jones E, editors. Cold Spring Harbor, NY: Cold Spring Harbor laboratory press; 1997. pp. 91\xe2\x80\x93227. <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=The+molecular+and+cellular+biology+of+the+yeast+Saccharomyces&amp;author=C+Kaiser&amp;author=R+Gimeno&amp;author=D+Shaywitz&amp;publication_year=1997&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR16">16. <span class="element-citation">Butland G, Babu M, D&#x000ed;az-Mej&#x000ed;a JJ, Bohdana F, Phanse S, Gold B, Yang W, Li J, Gagarinova AG, Pogoutse O, Mori H, Wanner BL, Lo H, Wasniewski J, Christopolous C, Ali M, Venn P, Safavi-Naini A, Sourour N, Caron S, Choi JY, Laigle L, Nazarians-Armavil A, Deshpande A, Joe S, Datsenko KA, Yamamoto N, Andrews BJ, Boone C, Ding H, Sheikh B, Moreno-Hagelseib G, Greenblatt JF, Emili A. eSGA: E. coli synthetic genetic array analysis. <span><span class="ref-journal">Nat Methods. </span>2008;<span class="ref-vol">5</span>(9):789\xe2\x80\x9395. doi: 10.1038/nmeth.1239.</span> [<a href="/pubmed/18677321" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1038%2Fnmeth.1239" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nat+Methods&amp;title=eSGA:+E.+coli+synthetic+genetic+array+analysis&amp;author=G+Butland&amp;author=M+Babu&amp;author=JJ+D&#x000ed;az-Mej&#x000ed;a&amp;author=F+Bohdana&amp;author=S+Phanse&amp;volume=5&amp;issue=9&amp;publication_year=2008&amp;pages=789-95&amp;pmid=18677321&amp;doi=10.1038/nmeth.1239&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR17">17. <span class="element-citation">Wang Y, Engels IH, Knee DA, Nasoff M, Deveraux QL, Quon KC. Synthetic lethal targeting of MYC by activation of the DR5 death receptor pathway. <span><span class="ref-journal">Cancer Cell. </span>2004;<span class="ref-vol">5</span>(5):501\xe2\x80\x9312. doi: 10.1016/S1535-6108(04)00113-8.</span> [<a href="/pubmed/15144957" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS1535-6108(04)00113-8" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cancer+Cell&amp;title=Synthetic+lethal+targeting+of+MYC+by+activation+of+the+DR5+death+receptor+pathway&amp;author=Y+Wang&amp;author=IH+Engels&amp;author=DA+Knee&amp;author=M+Nasoff&amp;author=QL+Deveraux&amp;volume=5&amp;issue=5&amp;publication_year=2004&amp;pages=501-12&amp;pmid=15144957&amp;doi=10.1016/S1535-6108(04)00113-8&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR18">18. <span class="element-citation">Click ES, Stearns T, Botstein D. Systematic structure-function analysis of the small GTPase Arf1 in yeast. <span><span class="ref-journal">Mol Biol Cell. </span>2002;<span class="ref-vol">13</span>(5):1652\xe2\x80\x9364. doi: 10.1091/mbc.02-01-0007.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC111134/">PMC free article</a>]</span> [<a href="/pubmed/12006660" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1091%2Fmbc.02-01-0007" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Mol+Biol+Cell&amp;title=Systematic+structure-function+analysis+of+the+small+GTPase+Arf1+in+yeast&amp;author=ES+Click&amp;author=T+Stearns&amp;author=D+Botstein&amp;volume=13&amp;issue=5&amp;publication_year=2002&amp;pages=1652-64&amp;pmid=12006660&amp;doi=10.1091/mbc.02-01-0007&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR19">19. <span class="element-citation">Wu TD, Schiffer CA, Gonzales MJ, Taylor J, Kantor R, Chou S, Israelski D, Zolopa AR, Fessel WJ, Shafer RW. Mutation patterns and structural correlates in human immunodeficiency virus type 1 protease following different protease inhibitor treatments. <span><span class="ref-journal">J Virol. </span>2003;<span class="ref-vol">77</span>(8):4836\xe2\x80\x9347. doi: 10.1128/JVI.77.8.4836-4847.2003.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC152121/">PMC free article</a>]</span> [<a href="/pubmed/12663790" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FJVI.77.8.4836-4847.2003" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Mutation+patterns+and+structural+correlates+in+human+immunodeficiency+virus+type+1+protease+following+different+protease+inhibitor+treatments&amp;author=TD+Wu&amp;author=CA+Schiffer&amp;author=MJ+Gonzales&amp;author=J+Taylor&amp;author=R+Kantor&amp;volume=77&amp;issue=8&amp;publication_year=2003&amp;pages=4836-47&amp;pmid=12663790&amp;doi=10.1128/JVI.77.8.4836-4847.2003&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR20">20. <span class="element-citation">Hoffman NG, Schiffer CA, Swanstrom R. Covariation of amino acid positions in HIV-1 protease. <span><span class="ref-journal">Virology. </span>2003;<span class="ref-vol">314</span>(2):536\xe2\x80\x9348. doi: 10.1016/S0042-6822(03)00484-7.</span> [<a href="/pubmed/14554082" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0042-6822(03)00484-7" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Virology&amp;title=Covariation+of+amino+acid+positions+in+HIV-1+protease&amp;author=NG+Hoffman&amp;author=CA+Schiffer&amp;author=R+Swanstrom&amp;volume=314&amp;issue=2&amp;publication_year=2003&amp;pages=536-48&amp;pmid=14554082&amp;doi=10.1016/S0042-6822(03)00484-7&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR21">21. <span class="element-citation">Vanet A, Val&#x000e8;re T, Muller-Trutwin M.  <span class="ref-journal">C.N.R.S. France.</span> 2001. Methods for identifying motifs and/or combinations of motifs having a boolean state of predetermined mutation. <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?title=C.N.R.S.+France&amp;author=A+Vanet&amp;author=T+Val&#x000e8;re&amp;author=M+Muller-Trutwin&amp;publication_year=2001&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR22">22. <span class="element-citation">Miller M, Jask&#x000f3;lski M, Rao JK, Leis J, Wlodawer A. Crystal structure of a retroviral protease proves relationship to aspartic protease family. <span><span class="ref-journal">Nature. </span>1989;<span class="ref-vol">337</span>(6207):576\xe2\x80\x939. doi: 10.1038/337576a0.</span> [<a href="/pubmed/2536902" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1038%2F337576a0" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Crystal+structure+of+a+retroviral+protease+proves+relationship+to+aspartic+protease+family&amp;author=M+Miller&amp;author=M+Jask&#x000f3;lski&amp;author=JK+Rao&amp;author=J+Leis&amp;author=A+Wlodawer&amp;volume=337&amp;issue=6207&amp;publication_year=1989&amp;pages=576-9&amp;pmid=2536902&amp;doi=10.1038/337576a0&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR23">23. <span class="element-citation">Swain AL, Miller MM, Green J, Rich DH, Schneider J, Kent SB, Wlodawer A. X-ray crystallographic structure of a complex between a synthetic protease of human immunodeficiency virus 1 and a substrate-based hydroxyethylamine inhibitor. <span><span class="ref-journal">Proc Natl Acad Sci U S. </span>1990;<span class="ref-vol">87</span>(22):8805\xe2\x80\x939. doi: 10.1073/pnas.87.22.8805.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC55048/">PMC free article</a>]</span> [<a href="/pubmed/2247451" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1073%2Fpnas.87.22.8805" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S&amp;title=X-ray+crystallographic+structure+of+a+complex+between+a+synthetic+protease+of+human+immunodeficiency+virus+1+and+a+substrate-based+hydroxyethylamine+inhibitor&amp;author=AL+Swain&amp;author=MM+Miller&amp;author=J+Green&amp;author=DH+Rich&amp;author=J+Schneider&amp;volume=87&amp;issue=22&amp;publication_year=1990&amp;pages=8805-9&amp;doi=10.1073/pnas.87.22.8805&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR24">24. <span class="element-citation">Deforche K, Camacho R, Grossman Z, Silander T, Soares MA, Moreau Y, Shafer RW, Van Laethem K, Carvalho AP, Wynhoven B, Cane P, Snoeck J, Clarke J, Sirivichayakul S, Ariyoshi K, Holguin A, Rudich H, Rodrigues R, Bouzas MB, Cahn P, Brigido LF, Soriano V, Sugiura W, Phanuphak P, Morris L, Weber J, Pillay D, Tanuri A, Harrigan PR, Shapiro JM, Katzenstein DA, Kantor R, Vandamme AM. &#x0003e;Bayesian network analysis of resistance pathways against HIV-1 protease inhibitors. <span><span class="ref-journal">Infect Genet Evol. </span>2007;<span class="ref-vol">7</span>(3):382\xe2\x80\x9390. doi: 10.1016/j.meegid.2006.09.004.</span> [<a href="/pubmed/17127103" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2Fj.meegid.2006.09.004" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Infect+Genet+Evol&amp;title=&#x0003e;Bayesian+network+analysis+of+resistance+pathways+against+HIV-1+protease+inhibitors&amp;author=K+Deforche&amp;author=R+Camacho&amp;author=Z+Grossman&amp;author=T+Silander&amp;author=MA+Soares&amp;volume=7&amp;issue=3&amp;publication_year=2007&amp;pages=382-90&amp;pmid=17127103&amp;doi=10.1016/j.meegid.2006.09.004&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR25">25. <span class="element-citation">Chen Z, Li Y, Chen E, Hall DL, Darke PL, Culberson C, Shafer JA, Kuo LC. Crystal structure at 1.9-A resolution of human immunodeficiency virus (HIV) II protease complexed with L-735,524, an orally bioavailable inhibitor of the HIV proteases. <span><span class="ref-journal">J Biol Chem. </span>1994;<span class="ref-vol">269</span>(42):26344\xe2\x80\x938.</span> [<a href="/pubmed/7929352" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Biol+Chem&amp;title=Crystal+structure+at+1.9-A+resolution+of+human+immunodeficiency+virus+(HIV)+II+protease+complexed+with+L-735,524,+an+orally+bioavailable+inhibitor+of+the+HIV+proteases&amp;author=Z+Chen&amp;author=Y+Li&amp;author=E+Chen&amp;author=DL+Hall&amp;author=PL+Darke&amp;volume=269&amp;issue=42&amp;publication_year=1994&amp;pages=26344-8&amp;pmid=7929352&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR26">26. <span class="element-citation">Harte WE, Jr, Swaminathan S, Mansuri MM, Martin JC, Rosenberg IE, Beveridge DL. Domain communication in the dynamical structure of human immunodeficiency virus 1 protease. <span><span class="ref-journal">Proc Natl Acad Sci U S. </span>1990;<span class="ref-vol">87</span>(22):8864\xe2\x80\x938. doi: 10.1073/pnas.87.22.8864.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC55060/">PMC free article</a>]</span> [<a href="/pubmed/2247458" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1073%2Fpnas.87.22.8864" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S&amp;title=Domain+communication+in+the+dynamical+structure+of+human+immunodeficiency+virus+1+protease&amp;author=WE+Harte&amp;author=S+Swaminathan&amp;author=MM+Mansuri&amp;author=JC+Martin&amp;author=IE+Rosenberg&amp;volume=87&amp;issue=22&amp;publication_year=1990&amp;pages=8864-8&amp;doi=10.1073/pnas.87.22.8864&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR27">27. <span class="element-citation">Piana S, Carloni P, Parrinello M. Role of conformational fluctuations in the enzymatic reaction of HIV-1 protease. <span><span class="ref-journal">J Mol Biol. </span>2002;<span class="ref-vol">319</span>(2):567\xe2\x80\x9383. doi: 10.1016/S0022-2836(02)00301-7.</span> [<a href="/pubmed/12051929" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS0022-2836(02)00301-7" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Mol+Biol&amp;title=Role+of+conformational+fluctuations+in+the+enzymatic+reaction+of+HIV-1+protease&amp;author=S+Piana&amp;author=P+Carloni&amp;author=M+Parrinello&amp;volume=319&amp;issue=2&amp;publication_year=2002&amp;pages=567-83&amp;pmid=12051929&amp;doi=10.1016/S0022-2836(02)00301-7&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR28">28. <span class="element-citation">Zoete V, Michielin O, Karplus M. Relation between sequence and structure of HIV-1 protease inhibitor complexes: a model system for the analysis of protein flexibility. <span><span class="ref-journal">J Mol Biol. </span>2002;<span class="ref-vol">315</span>(1):21\xe2\x80\x9352. doi: 10.1006/jmbi.2001.5173.</span> [<a href="/pubmed/11771964" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1006%2Fjmbi.2001.5173" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Mol+Biol&amp;title=Relation+between+sequence+and+structure+of+HIV-1+protease+inhibitor+complexes:+a+model+system+for+the+analysis+of+protein+flexibility&amp;author=V+Zoete&amp;author=O+Michielin&amp;author=M+Karplus&amp;volume=315&amp;issue=1&amp;publication_year=2002&amp;pages=21-52&amp;pmid=11771964&amp;doi=10.1006/jmbi.2001.5173&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR29">29. <span class="element-citation">Loeb DD, Swanstrom R, Everitt L, Manchester M, Stamper SE, Hutchison CA. Complete mutagenesis of the HIV-1 protease. <span><span class="ref-journal">Nature. </span>1989;<span class="ref-vol">340</span>(6232):397\xe2\x80\x93400. doi: 10.1038/340397a0.</span> [<a href="/pubmed/2666861" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1038%2F340397a0" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Nature&amp;title=Complete+mutagenesis+of+the+HIV-1+protease&amp;author=DD+Loeb&amp;author=R+Swanstrom&amp;author=L+Everitt&amp;author=M+Manchester&amp;author=SE+Stamper&amp;volume=340&amp;issue=6232&amp;publication_year=1989&amp;pages=397-400&amp;pmid=2666861&amp;doi=10.1038/340397a0&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR30">30. <span class="element-citation">Fernandez G, Clotet B, Martinez MA. Fitness landscape of human immunodeficiency virus type 1 protease quasispecies. <span><span class="ref-journal">J Virol. </span>2007;<span class="ref-vol">81</span>(5):2485\xe2\x80\x9396. doi: 10.1128/JVI.01594-06.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1865935/">PMC free article</a>]</span> [<a href="/pubmed/17151104" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FJVI.01594-06" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Fitness+landscape+of+human+immunodeficiency+virus+type+1+protease+quasispecies&amp;author=G+Fernandez&amp;author=B+Clotet&amp;author=MA+Martinez&amp;volume=81&amp;issue=5&amp;publication_year=2007&amp;pages=2485-96&amp;pmid=17151104&amp;doi=10.1128/JVI.01594-06&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR31">31. <span class="element-citation">Ullrich B, Laberge M, T&#x000f6;lgyesi F, Szeltner Z, Polg&#x000e1;r L, Fidy J. Trp42 rotamers report reduced flexibility when the inhibitor acetyl-pepstatin is bound to HIV-1 protease. <span><span class="ref-journal">Protein Sci. </span>2000;<span class="ref-vol">9</span>(11):2232\xe2\x80\x9345. doi: 10.1110/ps.9.11.2232.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2144495/">PMC free article</a>]</span> [<a href="/pubmed/11152134" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1110%2Fps.9.11.2232" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Protein+Sci&amp;title=Trp42+rotamers+report+reduced+flexibility+when+the+inhibitor+acetyl-pepstatin+is+bound+to+HIV-1+protease&amp;author=B+Ullrich&amp;author=M+Laberge&amp;author=F+T&#x000f6;lgyesi&amp;author=Z+Szeltner&amp;author=L+Polg&#x000e1;r&amp;volume=9&amp;issue=11&amp;publication_year=2000&amp;pages=2232-45&amp;pmid=11152134&amp;doi=10.1110/ps.9.11.2232&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR32">32. <span class="element-citation">De Meyer S, Azijn H, Surleraux D, Jochmans D, Tahri A, Pauwels R, Wigerinck P, de B&#x000e9;thune MP. TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolatse. <span><span class="ref-journal">Antimicrob Agents Chemother. </span>2005;<span class="ref-vol">49</span>(6):2314\xe2\x80\x9321. doi: 10.1128/AAC.49.6.2314-2321.2005.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1140553/">PMC free article</a>]</span> [<a href="/pubmed/15917527" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FAAC.49.6.2314-2321.2005" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Antimicrob+Agents+Chemother&amp;title=TMC114,+a+novel+human+immunodeficiency+virus+type+1+protease+inhibitor+active+against+protease+inhibitor-resistant+viruses,+including+a+broad+range+of+clinical+isolatse&amp;author=S+De+Meyer&amp;author=H+Azijn&amp;author=D+Surleraux&amp;author=D+Jochmans&amp;author=A+Tahri&amp;volume=49&amp;issue=6&amp;publication_year=2005&amp;pages=2314-21&amp;pmid=15917527&amp;doi=10.1128/AAC.49.6.2314-2321.2005&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR33">33. <span class="element-citation">Ammaranond P, Cunningham P, Oelrichs R, Suzuki K, Harris C, Leas L, Grulich A, Cooper DA, Kelleher AD. Rates of transmission of antiretroviral drug resistant strains of HIV-1. <span><span class="ref-journal">J Clin Virol. </span>2003;<span class="ref-vol">26</span>(2):153\xe2\x80\x9361. doi: 10.1016/S1386-6532(02)00114-2.</span> [<a href="/pubmed/12600647" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2FS1386-6532(02)00114-2" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Clin+Virol&amp;title=Rates+of+transmission+of+antiretroviral+drug+resistant+strains+of+HIV-1&amp;author=P+Ammaranond&amp;author=P+Cunningham&amp;author=R+Oelrichs&amp;author=K+Suzuki&amp;author=C+Harris&amp;volume=26&amp;issue=2&amp;publication_year=2003&amp;pages=153-61&amp;pmid=12600647&amp;doi=10.1016/S1386-6532(02)00114-2&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR34">34. <span class="element-citation">Svicher V, Ceccherini-Silberstein F, Erba F, Santoro M, Gori C, Bellocchi MC, Giannella S, Trotta MP, Monforte A, Antinori A, Perno CF. Novel human immunodeficiency virus type 1 protease mutations potentially involved in resistance to protease inhibitors. <span><span class="ref-journal">Antimicrob Agents Chemother. </span>2005;<span class="ref-vol">49</span>(5):2015\xe2\x80\x9325. doi: 10.1128/AAC.49.5.2015-2025.2005.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1087636/">PMC free article</a>]</span> [<a href="/pubmed/15855527" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FAAC.49.5.2015-2025.2005" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Antimicrob+Agents+Chemother&amp;title=Novel+human+immunodeficiency+virus+type+1+protease+mutations+potentially+involved+in+resistance+to+protease+inhibitors&amp;author=V+Svicher&amp;author=F+Ceccherini-Silberstein&amp;author=F+Erba&amp;author=M+Santoro&amp;author=C+Gori&amp;volume=49&amp;issue=5&amp;publication_year=2005&amp;pages=2015-25&amp;pmid=15855527&amp;doi=10.1128/AAC.49.5.2015-2025.2005&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR35">35. <span class="element-citation">Laurie AT, Jackson RM. Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites. <span><span class="ref-journal">Bioinformatics. </span>2005;<span class="ref-vol">21</span>(9):1908\xe2\x80\x9316. doi: 10.1093/bioinformatics/bti315.</span> [<a href="/pubmed/15701681" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1093%2Fbioinformatics%2Fbti315" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioinformatics&amp;title=Q-SiteFinder:+an+energy-based+method+for+the+prediction+of+protein-ligand+binding+sites&amp;author=AT+Laurie&amp;author=RM+Jackson&amp;volume=21&amp;issue=9&amp;publication_year=2005&amp;pages=1908-16&amp;pmid=15701681&amp;doi=10.1093/bioinformatics/bti315&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR36">36. <span class="element-citation">Hornak V, Okur A, Rizzo RC, Simmerling C. HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations. <span><span class="ref-journal">Proc Natl Acad Sci U S. </span>2006;<span class="ref-vol">103</span>(4):915\xe2\x80\x9320. doi: 10.1073/pnas.0508452103.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1347991/">PMC free article</a>]</span> [<a href="/pubmed/16418268" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1073%2Fpnas.0508452103" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S&amp;title=HIV-1+protease+flaps+spontaneously+open+and+reclose+in+molecular+dynamics+simulations&amp;author=V+Hornak&amp;author=A+Okur&amp;author=RC+Rizzo&amp;author=C+Simmerling&amp;volume=103&amp;issue=4&amp;publication_year=2006&amp;pages=915-20&amp;doi=10.1073/pnas.0508452103&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR37">37. <span class="element-citation">Perryman AL, Lin JH, McCammon JA. Restrained molecular dynamics simulations of HIV-1 protease: the first step in validating a new target for drug design. <span><span class="ref-journal">Biopolymers. </span>2006;<span class="ref-vol">82</span>(3):272\xe2\x80\x9384. doi: 10.1002/bip.20497.</span> [<a href="/pubmed/16508951" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1002%2Fbip.20497" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Biopolymers&amp;title=Restrained+molecular+dynamics+simulations+of+HIV-1+protease:+the+first+step+in+validating+a+new+target+for+drug+design&amp;author=AL+Perryman&amp;author=JH+Lin&amp;author=JA+McCammon&amp;volume=82&amp;issue=3&amp;publication_year=2006&amp;pages=272-84&amp;pmid=16508951&amp;doi=10.1002/bip.20497&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR38">38. <span class="element-citation">Wain-Hobson S, Sonigo P, Danos O, Cole S, Alizon M. Nucleotide sequence of the AIDS virus, LAV. <span><span class="ref-journal">Cell. </span>1985;<span class="ref-vol">40</span>(1):9\xe2\x80\x9317. doi: 10.1016/0092-8674(85)90303-4.</span> [<a href="/pubmed/2981635" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2F0092-8674(85)90303-4" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Cell&amp;title=Nucleotide+sequence+of+the+AIDS+virus,+LAV&amp;author=S+Wain-Hobson&amp;author=P+Sonigo&amp;author=O+Danos&amp;author=S+Cole&amp;author=M+Alizon&amp;volume=40&amp;issue=1&amp;publication_year=1985&amp;pages=9-17&amp;pmid=2981635&amp;doi=10.1016/0092-8674(85)90303-4&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR39">39. <span class="element-citation">Ibanez A, Clotet B, Martinez MA. Human immunodeficiency virus type 1 population bottleneck during indinavir therapy causes a genetic drift in the env quasispecies. <span><span class="ref-journal">J Gen Virol. </span>2000;<span class="ref-vol">81</span>(Pt 1):85\xe2\x80\x9395. doi: 10.1099/0022-1317-81-1-85.</span> [<a href="/pubmed/10640545" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1099%2F0022-1317-81-1-85" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Gen+Virol&amp;title=Human+immunodeficiency+virus+type+1+population+bottleneck+during+indinavir+therapy+causes+a+genetic+drift+in+the+env+quasispecies&amp;author=A+Ibanez&amp;author=B+Clotet&amp;author=MA+Martinez&amp;volume=81&amp;issue=Pt+1&amp;publication_year=2000&amp;pages=85-95&amp;pmid=10640545&amp;doi=10.1099/0022-1317-81-1-85&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR40">40. <span class="element-citation">Kitrinos KM, Nelson JA, Resch W, Swanstrom R. Effect of a protease inhibitor-induced genetic bottleneck on human immunodeficiency virus type 1 env gene populations. <span><span class="ref-journal">J Virol. </span>2005;<span class="ref-vol">79</span>(16):10627\xe2\x80\x9337. doi: 10.1128/JVI.79.16.10627-10637.2005.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1182671/">PMC free article</a>]</span> [<a href="/pubmed/16051855" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1128%2FJVI.79.16.10627-10637.2005" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Virol&amp;title=Effect+of+a+protease+inhibitor-induced+genetic+bottleneck+on+human+immunodeficiency+virus+type+1+env+gene+populations&amp;author=KM+Kitrinos&amp;author=JA+Nelson&amp;author=W+Resch&amp;author=R+Swanstrom&amp;volume=79&amp;issue=16&amp;publication_year=2005&amp;pages=10627-37&amp;pmid=16051855&amp;doi=10.1128/JVI.79.16.10627-10637.2005&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR41">41. <span class="element-citation">Rhee SY, Fessel WJ, Zolopa AR, Hurley L, Liu T, Taylor J, Nguyen DP, Slome S, Klein D, Horberg M, Flamm J, Follansbee S, Schapiro JM, Shafer RW. HIV-1 Protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug-resistance surveillance. <span><span class="ref-journal">J Infect Dis. </span>2005;<span class="ref-vol">192</span>(3):456\xe2\x80\x9365. doi: 10.1086/431601.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2597526/">PMC free article</a>]</span> [<a href="/pubmed/15995959" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1086%2F431601" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Infect+Dis&amp;title=HIV-1+Protease+and+reverse-transcriptase+mutations:+correlations+with+antiretroviral+therapy+in+subtype+B+isolates+and+implications+for+drug-resistance+surveillance&amp;author=SY+Rhee&amp;author=WJ+Fessel&amp;author=AR+Zolopa&amp;author=L+Hurley&amp;author=T+Liu&amp;volume=192&amp;issue=3&amp;publication_year=2005&amp;pages=456-65&amp;pmid=15995959&amp;doi=10.1086/431601&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR42">42. <span class="mixed-citation">Combet C, Garnier N, Charavay C, Grando D, Crisan D, Lopez J, Dehne-Garcia A, Geourjon C, Bettler E, Hulo C, Le Mercier P, Bartenschlager R, Diepolder H, Moradpour D, Pawlotsky JM, Rice CM, Tr&#x000e9;po C, Penin F, Del&#x000e9;age G: euHCVdb: the European hepatitis C virus database. Nucleic Acids Res. 2007, 363-6. 10.1093/nar/gkl970. 35 Database <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1669729/">PMC free article</a>]</span> [<a href="/pubmed/17142229" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>]</span></div><div class="ref-cit-blk half_rhythm" id="CR43">43. <span class="mixed-citation">Chang S, Zhang J, Liao X, Zhu X, Wang D, Zhu J, Feng T, Zhu B, Gao GF, Wang J, Yang H, Yu J, Wang J: Influenza Virus Database (IVDB): an integrated information resource and analysis platform for influenza virus research. Nucleic Acids Res. 2007, 376-80. 10.1093/nar/gkl779. 35 Database <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1781131/">PMC free article</a>]</span> [<a href="/pubmed/17065465" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>]</span></div><div class="ref-cit-blk half_rhythm" id="CR44">44. <span class="element-citation">Kuiken C, Korber B, Shafer RW. HIV sequence databases. <span><span class="ref-journal">AIDS Rev. </span>2003;<span class="ref-vol">5</span>(1):52\xe2\x80\x9361.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC2613779/">PMC free article</a>]</span> [<a href="/pubmed/12875108" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=AIDS+Rev&amp;title=HIV+sequence+databases&amp;author=C+Kuiken&amp;author=B+Korber&amp;author=RW+Shafer&amp;volume=5&amp;issue=1&amp;publication_year=2003&amp;pages=52-61&amp;pmid=12875108&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR45">45. <span class="mixed-citation">HIV Los Alamos National library. [<a href="http://www.hiv.lanl.gov/" data-ga-action="click_feat_suppl" ref="reftype=extlink&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=External%7CLink%7CURI" target="_blank">http://www.hiv.lanl.gov/</a>]</span></div><div class="ref-cit-blk half_rhythm" id="CR46">46. <span class="element-citation">Eddy SR. Profile hidden Markov models. <span><span class="ref-journal">Bioinformatics. </span>1998;<span class="ref-vol">14</span>(9):755\xe2\x80\x9363. doi: 10.1093/bioinformatics/14.9.755.</span> [<a href="/pubmed/9918945" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1093%2Fbioinformatics%2F14.9.755" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Bioinformatics&amp;title=Profile+hidden+Markov+models&amp;author=SR+Eddy&amp;volume=14&amp;issue=9&amp;publication_year=1998&amp;pages=755-63&amp;pmid=9918945&amp;doi=10.1093/bioinformatics/14.9.755&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR47">47. <span class="element-citation">Nickle DC, Jensen MA, Gottlieb GS, Shriner D, Learn GH, Rodrigo AG, Mullins JI. Consensus and ancestral state HIV vaccines. <span><span class="ref-journal">Science. </span>2003;<span class="ref-vol">299</span>(5612):1515\xe2\x80\x938. doi: 10.1126/science.299.5612.1515c.</span> [<a href="/pubmed/12624248" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1126%2Fscience.299.5612.1515c" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Consensus+and+ancestral+state+HIV+vaccines&amp;author=DC+Nickle&amp;author=MA+Jensen&amp;author=GS+Gottlieb&amp;author=D+Shriner&amp;author=GH+Learn&amp;volume=299&amp;issue=5612&amp;publication_year=2003&amp;pages=1515-8&amp;pmid=12624248&amp;doi=10.1126/science.299.5612.1515c&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR48">48. <span class="element-citation">Korber B, Muldoon M, Theiler J, Gao F, Gupta R, Lapedes A, Hahn BH, Wolinsky S, Bhattacharya T. Timing the ancestor of the HIV-1 pandemic strains. <span><span class="ref-journal">Science. </span>2000;<span class="ref-vol">288</span>(5472):1789\xe2\x80\x9396. doi: 10.1126/science.288.5472.1789.</span> [<a href="/pubmed/10846155" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1126%2Fscience.288.5472.1789" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Science&amp;title=Timing+the+ancestor+of+the+HIV-1+pandemic+strains&amp;author=B+Korber&amp;author=M+Muldoon&amp;author=J+Theiler&amp;author=F+Gao&amp;author=R+Gupta&amp;volume=288&amp;issue=5472&amp;publication_year=2000&amp;pages=1789-96&amp;pmid=10846155&amp;doi=10.1126/science.288.5472.1789&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR49">49. <span class="element-citation">Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. <span><span class="ref-journal">J R Stat Soc Ser. </span>1995;<span class="ref-vol">57</span>:289\xe2\x80\x93300.</span> <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+R+Stat+Soc+Ser&amp;title=Controlling+the+false+discovery+rate:+a+practical+and+powerful+approach+to+multiple+testing&amp;author=Y+Benjamini&amp;author=Y+Hochberg&amp;volume=57&amp;publication_year=1995&amp;pages=289-300&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR50">50. <span class="element-citation">Storey JD, Tibshirani R. Statistical significance for genomewide studies. <span><span class="ref-journal">Proc Natl Acad Sci U S. </span>2003;<span class="ref-vol">100</span>(16):9440\xe2\x80\x935. doi: 10.1073/pnas.1530509100.</span> <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC170937/">PMC free article</a>]</span> [<a href="/pubmed/12883005" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1073%2Fpnas.1530509100" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=Proc+Natl+Acad+Sci+U+S&amp;title=Statistical+significance+for+genomewide+studies&amp;author=JD+Storey&amp;author=R+Tibshirani&amp;volume=100&amp;issue=16&amp;publication_year=2003&amp;pages=9440-5&amp;doi=10.1073/pnas.1530509100&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR51">51. <span class="element-citation">Richmond TJ. Solvent accessible surface area and excluded volume in proteins. Analytical equations for overlapping spheres and implications for the hydrophobic effect. <span><span class="ref-journal">J Mol Biol. </span>1984;<span class="ref-vol">178</span>(1):63\xe2\x80\x9389. doi: 10.1016/0022-2836(84)90231-6.</span> [<a href="/pubmed/6548264" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>] [<a href="//dx.doi.org/10.1016%2F0022-2836(84)90231-6" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CCrosslink%7CDOI">CrossRef</a>] <span class="nowrap">[<a href="https://scholar.google.com/scholar_lookup?journal=J+Mol+Biol&amp;title=Solvent+accessible+surface+area+and+excluded+volume+in+proteins.+Analytical+equations+for+overlapping+spheres+and+implications+for+the+hydrophobic+effect&amp;author=TJ+Richmond&amp;volume=178&amp;issue=1&amp;publication_year=1984&amp;pages=63-89&amp;pmid=6548264&amp;doi=10.1016/0022-2836(84)90231-6&amp;" target="pmc_ext" ref="reftype=other&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Content%20Provider%7CLink%7CGoogle%20Scholar">Google Scholar</a>]</span></span></div><div class="ref-cit-blk half_rhythm" id="CR52">52. <span class="mixed-citation">Alland C, Moreews F, Boens D, Carpentier M, Chiusa S, Lonquety M, Renault N, Wong Y, Cantalloube H, Chomilier J, Hochez J, Pothier J, Villoutreix BO, Zagury JF, Tuff&#x000e9;ry P: RPBS: a web resource for structural bioinformatics. Nucleic Acids Res. 2005, 44-9. 10.1093/nar/gki477. 33 Web Server <span class="nowrap">[<a class="int-reflink" href="/pmc/articles/PMC1160237/">PMC free article</a>]</span> [<a href="/pubmed/15980507" target="pmc_ext" ref="reftype=pubmed&amp;article-id=2898770&amp;issue-id=354832&amp;journal-id=3814&amp;FROM=Article%7CCitationRef&amp;TO=Entrez%7CPubMed%7CRecord">PubMed</a>]</span></div></div></div></div><!--post-content--></div>\n            \n            \n        \n            \n        </div>\n        <!-- Book content -->\n    </div>\n    \n    <div id="rightcolumn" class="four_col col last">\n        <!-- Custom content above discovery portlets -->\n        <div class="col6">\n            \n        </div>\n        \n        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><div class="format-menu"><h2>Formats:</h2><ul><li class="selected">Article</li> | <li><a href="/pmc/articles/PMC2898770/?report=reader">PubReader</a></li> | <li class="epub-link"><a href="/pmc/articles/PMC2898770/epub/">ePub (beta)</a></li> | <li><a href="/pmc/articles/PMC2898770/pdf/13062_2010_Article_223.pdf">PDF (1.6M)</a></li> | <li><a href="#" data-citationid="PMC2898770" class="citationexporter ctxp">Citation</a></li></ul></div></div><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="share-buttons"><h2>Share</h2><ul><li class="facebook"><a href="https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2898770%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047626" alt="Share on Facebook" />\n                             Facebook\n                        </a></li><li class="twitter"><a href="https://twitter.com/intent/tweet?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2898770%2F&amp;text=Co-lethality%20studied%20as%20an%20asset%20against%20viral%20drug%20escape%3A%20the%20HIV%20protease%20case"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047627" alt="Share on Twitter" />\n                             Twitter\n                        </a></li><li class="gplus"><a href="https://plus.google.com/share?url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2898770%2F"><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/img/4047628" alt="Share on Google Plus" />\n                             Google+\n                        </a></li></ul></div>\n        \n        <div id="ajax-portlets" data-pmid="20565756" data-aiid="7096855" data-aid="2898770" data-iid="354832" data-domainid="3814" data-domain="phenaturepg" data-accid="PMC2898770" data-md5="5b07d6b50500e02d11bba19c093e114c"></div>\n                \n        <!-- Custom content below discovery portlets -->\n        <div class="col7">\n            \n        </div>\n    </div>\n</div>\n\n<!-- Custom content after all -->\n<div class="col8">\n    \n</div>\n<div class="col9">\n    \n</div>\n\n<script src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>\n<script>\n    (function($){\n        $(\'.skiplink\').each(function(i, item){\n            var href = $($(item).attr(\'href\'));\n            href.attr(\'tabindex\', \'-1\').addClass(\'skiptarget\'); // ensure the target can receive focus\n            $(item).on(\'click\', function(event){\n                event.preventDefault();\n                $.scrollTo(href, 0, {\n                    onAfter: function(){\n                        href.focus();\n                    }\n                });\n            });\n        });\n    })(jQuery);\n</script>\n\n\n\n<div id="body-link-poppers"></div>\n                        </div>\n                        <div class="bottom">\n                            \n                            <div id="NCBIFooter_dynamic">\n    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>\n    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2020-04-17T20:43:37-04:00&amp;Snapshot=%2Fprojects%2FPMC%2FPMCViewer@4.46&amp;Host=ptpmc102&amp;ncbi_phid=8A1B093EE9A3EA01000000000661065E&amp;ncbi_session=8A1B093EE9A4D381_1633SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fpmc%2Farticles%2FPMC2898770%2F&amp;Db=pmc&amp;folderID=132&amp;Ncbi_App=pmc&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>\n    \n</div>\n\n                            <div class="footer" id="footer">\n    \n    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>\n    <div id="external-disclaimer" class="offscreen_noflow">\n        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.\n    </div>    \n    <div id="ncbifooter" class="contact_info">      \n        <div id="footer-contents-right">\n            <div id="nlm_thumb_logo">\n                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>\n            </div>\n            <div id="nih_thumb_logo">\n                <a href="https://www.nih.gov" title="NIH">NIH</a>\n            </div>\n            <div id="hhs_thumb_logo">\n                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>\n            </div>\n            <div id="usagov_thumb_logo">\n                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>\n            </div>         \n        </div>\n        \n        <div id="footer-contents-left">\n            <p class="address vcard">\n                <span class="url">\n                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for\n                        Biotechnology Information</a>,\n                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>\n                <span class="adr">\n                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>\n                    <span class="region">MD</span>, <span class="postal-code">20894</span>\n                    <span class="country-name">USA</span>\n                </span>\n            </p>\n            \n            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>\n        </div>\n    </div>\n    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    \n    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>\n</div>\n                        </div>\n                    </div>\n                    <!--/.page-->\n                </div>\n                <!--/.wrap-->\n            </div><!-- /.twelve_col -->\n        </div>\n        <!-- /.grid -->\n\n        <span class="PAFAppResources"></span>\n        \n        <!-- BESelector tab -->\n        \n        \n        \n        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=pmc&amp;ncbi_pdid=article&amp;ncbi_acc=&amp;ncbi_domain=phenaturepg&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/articles/PMC2898770/&amp;ncbi_app=pmc" /></noscript>\n        \n        \n        <!-- usually for JS scripts at page bottom -->\n        <!--<component id="PageFixtures" label="styles"></component>-->\n    \n\n<!-- 8A1B093EE9A4D381_1633SID /projects/PMC/PMCViewer@4.46 ptpmc102 v4.1.r585844 Mon, May 06 2019 02:53:16 -->\n\n<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4160049/js/3879255/4121861/3818874/4168176/3821238/4117325/4087685/4072593/4076480/3921943/4105668/4065628.js" snapshot="pmc"></script></body>\n</html>'